FORM PTO-1390 (REV 10-95) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 0380-P02370US0

U.S. APPLICATION NO. (If known, see 37 CFR 1.5): 09/719261

INTERNATIONAL APPLICATION NO	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB99/01824	9 June 1999	10 June 1998

TITLE OF INVENTION: PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

APPLICANT(S) FOR DO/EO/US: MATASSA, Victor et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [XX] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [ ] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. [XX] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date
5. [XX] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).
   b. [X] has been transmitted by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [ ] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. [XX] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
   b. [ ] have been transmitted by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendemnts has NOT expired.
   d. [X] have not been made and will not be made.
8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. [ ] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [ ] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [ ] A FIRST preliminary amendment.
    [ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [XX] Other items or information:

Copy of Form PCT/IB/308 (July 1996)

09/719261 .072301

JC01 Rec'd PCT/PTO 08 DEC 2000

U.S. APPLICATION NO (if known, see 37 CFR 1.5) 09/719261	INTERNATIONAL APPLICATION NO PCT/GB99/01824	ATTORNEY'S DOCKET NUMBER 0380-P02370US0

	CALCULATIONS PTO USE ONLY	
17. [XX] The following fees are submitted:		
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :		
Search Report has been prepared by the EPO or JPO		
International preliminary examination fee paid to USPTO (37 CFR 1.482)		
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))		
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO		
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)		
ENTER APPROPRIATE BASIC FEE AMOUNT =	$ 860.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	$ 130.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	29 - 20 =	9	X 18.00	$ 162.00	
Independent claims	1 - 3 =	0	X 80.00	$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 270.00	$ 0.00	
	TOTAL OF ABOVE CALCULATIONS =			$ 1,152.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also by filed (Note 37 CFR 1.9, 1.27, 1.28).				$ 0.00	
	SUBTOTAL =			$ 1,152.00	
Processing fee of **$130.00** for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				$ 0.00	
	TOTAL NATIONAL FEE =			$ 1,152.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **$40.00** per property +				$ 0.00	
	TOTAL FEES ENCLOSED =			$ 1,152.00	
				Amount to be: refunded	$
				charged	$

a. [XX] A check in the amount of $ 1,152.00 to cover the above fees is enclosed.

b. [ ] Please charge my Deposit Account No. _____ in the amount of $_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [XX] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1406 . A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

HAGAN, Patrick J.
Dann Dorfman Herrell and Skillman, P.C.
1601 Market Street, Suite 720
Philadelphia, Pennsylvania 19103
United States of America

Patrick J. Hagan
SIGNATURE

Patrick J. Hagan
NAME

27,643
REGISTRATION NUMBER

THE UNITED STATES PATENT AND TRADEMARK OFFICE

United States Serial No.	:	Not yet assigned
International Application No.	:	PCT/GB99/01824
International Filing Date	:	June 9, 1999
Inventors	:	Victor Matassa et al.
Title	:	PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

Suite 720
1601 Market Street
Philadelphia, PA 19103-2307
(215) 563-4100 (telephone)
(215) 563-4044 (facsimile)
Our File: 0380-P02370US0

Box PCT
Assistant Commissioner
for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Before calculation of the filing fee, please amend the claims of the above-referenced patent application as follows:

In the claims:

Please amend the claims as follows:

In claim 5, lines 2-3, delete "any one of the preceding claims" and insert therefor --claim 1--.

In claim 7, lines 1-2, delete "any one of the preceding claims" and insert therefor --claim 1--.

In claim 9, line 2, delete "or claim 8".

In claim 11, line 2, delete "or claim 10".

In claim 15, lines 1-2, delete "or 14".

In claim 16, lines 1-2, delete "any one of claims 13 to 15" and insert therefor --claim 13--.

In claim 17, line 1, delete "any one of claims 13 to 16" and insert therefor --claim ___--.

In claim 24, after line, delete ", especially 

"

In claim 28, lines 2-3, delete "any one of claims 1 to 25" and insert therefor --claim 1--.

In claim 29, lines 5-7 delete ", or a fluorine containing oligopeptide salt or ester of any one of claims 1 to 25".

In claim 30, lines 1-2, delete "any one of claims 1-25" and insert therefor --claim 1--.

Add the following new claim:

31. A dipeptide salt or ester according to claim 24, wherein R_{13} is a group of the formula 

Delete claims 26 and 27.

REMARKS

The purpose of this Preliminary Amendment is to delete multiple claims dependencies and to conform certain of the claims to United States Patent and Trademark Office practice.

The foregoing amendments do not introduce new matter into the present application. Therefore none of these amendments should be considered objectionable, and entry thereof is respectfully requested.

Respectfully submitted,

Patrick J. Hagan

Patrick J. Hagan
Reg. No. 27,643
Attorney for Applicant

PJH:ksk

PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

TECHNICAL FIELD

This invention relates to compounds which can act as inhibitors of the hepatitis C virus (HCV) NS3 protease, to uses of such compounds and to their preparation.

BACKGROUND ART

The hepatitis C virus (HCV) is the major causative agent of parenterally-transmitted and sporadic non-A, non-B hepatitis (NANB-H). Some 1% of the human population of the planet is believed to be affected. Infection by the virus can result in chronic hepatitis and cirrhosis of the liver, and may lead to hepatocellular carcinoma. Currently no vaccine nor established therapy exists, although partial success has been achieved in a minority of cases by treatment with recombinant interferon-α, either alone or in combination with ribavirin. There is therefore a pressing need for new and broadly-effective therapeutics.

Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (NS2-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B). The NS3 protease is located in the N-terminal domain of the NS3 protein, and is considered a prime drug target since it is responsible for an intramolecular cleavage at the NS3/4A site and for downstream intermolecular processing at the NS4A/4B, NS4B/5A and NS5A/5B junctions.

Previous research has identified classes of peptides, in particular hexapeptides, showing degrees of activity in inhibiting the NS3 protease. The aim of the present

invention is to provide further compounds which exhibit similar, and if possible improved, activity.

DISCLOSURE OF INVENTION

The present inventors investigated the replacement of cysteine by 4,4-difluoro-2-aminobutyric acid or 4,4,4-trifluoro-2-aminobutyric acid at the P1 position of certain peptidic product inhibitors and substrates of HCV NS3 serine protease. These studies have shown that fluorocarbon groups, in particular the $-CF_2H$ group may mimic the cysteine thiol group, which is believed to be involved in substrate and inhibitor binding to the S1 specificity pocket of the NS3 protease. In general terms, therefore, the present invention relates to compounds containing fluorocarbon groups, especially $-CF_2H$ and $-CF_3$, for use as inhibitors of HCV NS3 protease. Examples of such compounds include peptides or peptide analogs, in which a fluorocarbon group, such as $-CF_2H$, is present as a sidechain, for instance at the C-terminus or P1 position of the peptide.

Definitions

In the discussion of the invention which follows certain terms are used repeatedly. Therefore, we seek to define each at the outset. Where definitions in the text differ from those given here it should be understood that the possibilities set out are those which are preferred among the broader definitions set out here.

By "lower alkyl" and "lower alkoxy" are intended groups having from 1 to 10, preferably 1 to 6, most preferably 1 to 4 carbon atoms. "Lower alkenyl" groups have from 2 to 10, preferably 2 to 6 carbon atoms.

The term "aryl" as used herein is intended to encompass

heteroaromatic groups and implies an aromatic (heteroaromatic) ring optionally fused, e.g. benzofused, with one to three cycloalkyl, aromatic, heterocyclic or heteroaromatic rings. Preferred groups containing a carbocyclic aromatic radical have from 6 to 14 more preferably 6 to 10 carbon atoms. Examples of such groups include phenyl and naphthyl. Heteroaryl groups include a 3 to 7 membered heterocyclic aromatic ring consisting of one or more carbon atoms and from one to four heteroatoms selected from nitrogen, oxygen and sulphur. Aryl groups, in general, contain from 1 to 14 carbon atoms, preferably 3 to 10 carbon atoms.

Aralkyl and aralkyloxy- groups generally contain from 2 to 20, preferably 4 to 15 carbon atoms.

Optional substituents may be selected from the following list: lower alkyl or alkenyl, aryl, lower alkoxy, amino, nitro, halo, hydroxy, carboxylic acid, acyl, formyl, acylsulphonamide, ester, amide, cyano, and trihalomethyl groups. As appropriate an optional substituent may itself be substituted by another substituent.

Where a group is described as "optionally interrupted" it may contain at lest one of the following:



where R is hydrogen, or an alkyl, e.g. lower alkyl, alkenyl, e.g. lower alkenyl, aryl or aralkyl group.

MODES FOR CARRYING OUT THE INVENTION

According to a first aspect of the invention there is provided a peptide of formula (I):

Y-B-A-X

as well as pharmaceutically acceptable salts and esters thereof.

The Group A

In this formula A is an amino acid residue of formula:



where m is 0 or 1. Preferably, m is 0.

The Group B

B is also a naturally or non-naturally occurring amino acid residue of formula:



wherein R_2 is a non-polar side chain or includes an acidic functionality. Essentially hydrophobic, polar but uncharged side chains may also be suitable. Typical R_2 groups contain from 1 to 20, preferably from 1 to 13 and particularly preferably between 1 and 8 carbon atoms. The side chain, R_2, may be aliphatic or aromatic, saturated or unsaturated, branched or unbranched, substituted or unsubstituted. The side chain may contain, in addition to carbon and hydrogen, heteroatoms such as nitrogen, oxygen, sulphur and phosphorus. Preferred substituent groups include the halogens, especially fluorine. In general, the "acidic functionality" is a carboxylic acid group, but the term as used herein encompasses acid mimetics such as tetrazoles and acylsulphonamides. Examples of suitable side chains, R_2 include those of glutamic acid and aspartic acid, 2-aminobutyric acid, 4,4-difluoro-2-

aminobutyric acid, alanine, isoleucine, valine, leucine, cysteine, phenylalanine, naphthylalanine and β-cyclohexylalanine. Of these, the side chains of cyclohexylalanine and leucine are particularly preferred. The "side chain" present in proline may also be suitable in which case the group R_2 forms a ring with the adjacent nitrogen, and the hydrogen placed in parenthesis in the above formula is absent.

The Group X

X is selected from the following:
$-CO_2R_8$; $-H$; $-OR_8$; $-CF_3$; $-CONR_9R_{10}$; $-CF_2CONR_9R_{10}$; $-NHSO_2R_{25}$ or a heterocyclic group of formula:



wherein U is sulphur, oxygen or NR_{11}; R_8, R_9, R_{10} and R_{11} are, independently, hydrogen or any suitable aliphatic or aromatic groups such as, in particular, lower alkyl, lower alkenyl, aryl, or aralkyl groups, and S and T are each independently either H or R_{12}, where R_{12} is a lower alkyl, lower alkenyl, aryl or aralkyl group, or can together form a ring, such as a 5 or 6 membered ring, preferably an aromatic ring such as a phenyl ring.

R_9 is preferably hydrogen, R_{11} is preferably hydrogen, and preferred examples of R_{10} include benzyl and phenethyl.

Preferred choices for the group X are: $-CO_2H$ and $-CONHCH_2Ph$,



H, -OH, or $-NHSO_2R_{25}$.

The Group Y

(i) The N-terminal group, designated Y, may be a group of formula:



wherein, C is a naturally or non-naturally occurring amino acid residue having a non-polar, polar but uncharged, or acidic side chain. Generally, side chains within the definition R_2 above are also suitable as side chains at C and examples of amino acids given above for B apply also to C. In this case isoleucine and glutamic acid are particularly preferred, though others such as those discussed below under the heading "tripeptides" may also be used to advantage.

D may be absent (in which case E and F will also be absent), but where present is a naturally or non-naturally occurring amino acid having a hydrophobic side group. This side group may include from 1 to 20, and preferably 1 to 13 carbon atoms. Provided that the essentially hydrophobic character of the side group is retained it may be aliphatic or aromatic, saturated or unsaturated, branched or unbranched, substituted or unsubstituted. The side chain may contain, in addition to carbon and hydrogen, heteroatoms such as nitrogen, oxygen, sulphur and phosphorus. Preferred substituent

groups include the halogens, especially fluorine. Examples of suitable residues include methionine, isoleucine, leucine, norleucine, valine, methyl valine, phenylglycine, phenylalanine or diphenylalanine. Among these leucine and, particularly, diphenylalanine are preferred.

E (together with F) may be absent, but if present is generally a naturally or non-naturally occurring amino acid having a side chain which includes an acidic functionality. Preferred examples are glutamic and aspartic acid, with the former being particularly preferred. E may, alternatively, be a naturally or non-naturally occurring amino acid having a non-polar, or polar but uncharged side chain. Of the non-polar amino acids, phenylalanine, diphenylalanine, isoleucine and valine are preferred, especially the D-enantiomers. Among the polar amino acids suitable examples are tyrosine and 4-nitrophenylalanine. Alternatively where F, but not E, is absent (see below), E may be a dicarboxylic acid containing up to 10 carbon atoms preferably up to 6 carbon atoms and lacking the amino group of acidic amino acids. Suitable examples are glutaric and succinic acid.

F may be absent (either by itself, or together with E), but when present is an amino acid or analogue having a side chain including acidic functionality. Aspartic acid is preferred, although glutamic acid is another possibility. Like E, F may also be a dicarboxylic acid containing up to 10, preferably up to 6 carbon atoms, and lacking the amino group of acidic amino acids. Examples are glutaric and succinic acid.

In general, the side chains at E and F may include from 1 to 20, preferably 1 to 13, and particularly preferably 1 to 8 carbon atoms. They may be aliphatic or aromatic, saturated or unsaturated, branched or unbranched, substituted or unsubstituted. The side chain may contain, in addition to carbon and hydrogen, heteroatoms such as nitrogen, oxygen, sulphur and phosphorus. Preferred substituent groups include the halogens, especially fluorine.

Z may be absent (especially in the case where the N terminus of Y is an E or F group and this is a dicarboxylic acid lacking an amino group). Where present, however, it may be a hydrogen atom or a group of formula R_7CO-, where R_7 is chosen such that the group R_7CO, together with the nitrogen atom to which the group is bonded forms an amide, urethane or urea linkage. R_7 contains from 1 to 20 carbon atoms, preferably 1 to 15, particularly 4 to 9 carbon atoms and is an alkyl, aryl or aralkyl group, alkyloxy, aryloxy or aralkyloxy group, alkylamino, arylamino or aralkylamino group. In general, R_7 is a relatively small hydrophobic group but it may be substituted for instance with one or more trifluoromethyl substituents or with carboxylic acid groups which may, optionally be esterified, e.g. with a C_{1-4} alkyl group. Preferred examples of R_7 include: $ArCH_2O-$ and $ArCH_2NH-$, in which Ar is an optionally substituted aryl (preferably phenyl) group. Preferred optional substituents include the halogens, carboxylic acid, carboxylic acid esters and $-CF_3$ groups. Alternatively, preferred R_7 groups include lower alkyloxy groups, especially tBuO-. These groups are particularly preferred in the case

of molecules containing just three amino acid residues. In the case of molecules containing four or more residues simple R_7 groups such as lower alkyl, especially methyl may be preferable.

(ii) Alternatively, instead of being an amino acid or oligopeptide of formula Z-F-E-D-C-, the N-terminal group Y may be a group of formula $R_{13}CO$- where R_{13} is an aliphatic or aromatic group containing from 1 to 25, preferably 4-21, particularly 4 to 16 carbon atoms and 0-5 oxygen atoms, 0-3 nitrogen atoms, 0 to 2 sulphur atoms and up to 9 other heteroatoms (especially halogen atoms) which may be the same or different. Preferred groups, R_{13}, contain an acidic functionality (especially a carboxylic acid or acylsulphonamide group) or an indoline group.

Substituent groups, R_{13}, which contain an acidic functionality, such as $-CO_2H$ preferably also include a relatively hydrophobic group such as $C_{3\ to\ 8}$ alkylene (which may be branched), cyclopentyl, cyclohexyl, or aryl, especially optionally substituted phenyl or thienyl groups. Optional substituents include halogens, C_{1-8} alkyl and alkoxy groups and $-CF_3$ groups.

Some examples of R_{13} groups including a carboxylic acid group may be represented by the general formula:



wherein each R_a is independently selected from hydrogen, lower alkyl (especially methyl), lower alkenyl, lower alkoxy, optionally substituted aryl or aralkyl groups (such as those substituted with halogen, $-CF_3$ or lower alkyl or alkoxy groups) or two R_a taken together result in the formation of a three to seven membered aliphatic or aromatic ring which optionally contains at least one heteroatom. In the case where two R_a taken together result in the formation of a ring containing unsaturation, especially an aromatic ring, then other R_a may be absent.

Optionally one or more groups



may be replaced by -O-. Preferably no more than one such group is replaced.

A preferred subclass of these compounds are those of formula



especially those compounds in which each R_a is independently selected from hydrogen, methyl, optionally substituted phenyl or two R_a on the same carbon atom together form a cyclopentyl, cyclohexyl, or a five or six membered cyclic ketal. Examples of

such compounds are those of formulae 7d, 7e, 7f, 7j, 7k, 7l, 7o, 7p and 7q in Table 3 infra.

Another preferred subclass is



such as compounds 8b, 8c, 8d, 8e and 8g in Table 3.

The carboxylic acid group in any of this preferred class of compounds may be esterified for instance as a lower alkyl ester such as a methyl ester.

The -OH group of the carboxylic acid group may also optionally be replaced by an $-SO_2NH-$ group, especially by $Ph-SO_2-NH-$ (e.g. compound 7n of Table 3).

Other preferred substituent groups R_{13} have the formula



where R_{14} is a cycloalkyl (C_{3-7}, but especially cyclohexyl) or optionally substituted aryl group. Optional substituents include C_{1-8} alkoxy, halogen or $-CF_3$ but preferably R_{14} is an unsubstituted cyclohexyl, phenyl or thienyl group.

Another possibility is that R_{13} is an indoline group

of formula



where R_{15} is hydrogen, an optionally branched, optionally interrupted and optionally substituted lower alkyl or lower alkenyl group or an optionally substituted aralkyl group R_{16} is hydrogen or an optionally substituted and optionally interrupted lower alkoxy or aryloxy- group.

Preferred optional interruptions in the group R_{15} include -O-. A preferred substituent is $-CO_2H$, optionally as a lower alkyl ester. When R_{15} is an aralkyl group it is preferably an optionally substituted benzyl- or thienylmethyl- group. Preferred optional substituents in the benzene ring include halogens, especially chlorine, lower alkoxy (e.g. -OMe) and aryloxy (e.g. PhO-) groups cyano-, and carboxylic acid groups. Carboxylic acid groups, optionally in the form of lower alkyl esters are especially preferred. The preferred position of substitution depends on the particular aryl group substituted, and the nature of the substituent. In the case where R_{15} is a benzyl group, substitution is preferably ortho-, or meta- to the $-CH_2-$ group.

The substituent R_{16}, when present is preferably at the 6-position of the ring system. Optional substituents of R_{16} include carboxylic acid groups, possibly as lower alkyl esters. Possible

interrupting groups include: -O-, $-SO_2-$, -CO-, -OCO-, -CO.O-, -NH-, -NH.CO-, and -CO.NH-. Of these -O- and $-SO_2-$ are preferred.

In another embodiment R_{13} is a group of formula:



where R_{15} is as defined above.

In a still further embodiment it is an optionally substituted indole group of formula:



where each of R_{17}, R_{18} and R_{19}, independently, is selected from hydrogen, optionally substituted lower alkyl, lower alkenyl and lower alkoxy, optionally substituted aryl, aralkyl, aryloxy or aralkoxy, a carboxylic acid group optionally as its lower alkyl ester, a halogen, cyano, or CF_3 group.

Tables 3 and 4 list, under the column "structure" certain other possibilities for R_{13}.

Stereochemistry

Generally, each naturally or non-naturally occurring

amino acid, (A-F) may have D- or L-stereochemistry, but L-stereochemistry is generally preferred. However, either D- or L-stereochemistry is allowed at amino acid A, although in general the L isomer is preferred. Particularly preferably, all the naturally or non-naturally occurring amino acid residues in the peptides of this aspect of the invention are L-isomers.

Compounds of this aspect of the invention may be substantially pure single stereoisomers, or may be mixtures of stereoisomers, especially of diastereoisomers having different stereochemistry at the A amino acid only.

The first aspect of the invention includes certain preferred classes of compound as will now be discussed.

(1) "Dipeptides"

Preferred dipeptides of the first aspect of the invention are ketoacids; that is, the group X is preferably a $-CO_2H$ group.

The amino acid residue A of preferred dipeptides has m=0. Preferred compounds have leucine, or cyclohexyl alanine as residue B.

Particularly preferred dipeptides are those of formula:



where Y' is a group selected from those discussed at (ii) above. Examples are given in tables 3 and 4.

(2) "Tripeptides"

In preferred tripeptides of the first aspect of the invention, X is preferably -H or $-CO_2H$, of which the latter is particularly preferred. As in the dipeptides, m is preferably 0.

Preferred residues at B are cyclohexylalanine, leucine, α-amino butyric acid, 4,4-difluoro-2-aminobutyric acid and phenylalanine, with leucine being particularly preferred.

Thus, particularly preferred C-terminal portions (-B-A-X) of the tripeptides are represented by the following formulae:











Preferred amino acids for inclusion as amino acid "C" of the tripeptide, for instance in conjunction with one of the particularly preferred C terminal portions set out above include alanine, isoleucine, leucine, phenylalanine, valine, norleucine, norvaline, glutamic acid, glutamine, aspartic acid, α-t-butyl glycine, styrylalanine, homoleucine, 3,5 dichlorophenylalanine 2-thienylalanine, 3-bromophenylalanine and α-cyclopentyl glycine.

Particularly preferred C-terminal portions including these amino acids include the following:









5









































As indicated above, various N-terminal groups are possible and preferably result in the formation of an amide, urethane or urea linkage. The following are among the preferred N-terminal groups for tripeptides:















Specific examples of tripeptides in accordance with the first aspect of the invention, together with their IC_{50}s are set out below at Table 2.

(3) Tetrapeptides

Preferred C-terminal "X" groups for inclusion in tetrapeptides of the invention are $-CO_2H$ (optionally in the form of its ester) and $-CONR_9R_{10}$ where R_9 and R_{10} are as defined above. As in the other series, "m" is preferably O.

Any of the tripeptide fragments described above may be extended at the C-terminus by addition of an amino acid within the definition "D" above. Diphenylalanine is particularly preferred.

A particularly preferred tetrapeptide unit: D-C-B-A is:



which may be joined at its N- and C- termini to any of the X or Z groups set out above.

Preferred tetrapeptides are set out in Table 2.

(4) Hexapeptides

Hexapeptides in accordance with the first aspect of the invention are compounds of formula:

Z-F-E-D-C-B-A-X

where A-F, X and Z are defined above. "m" is preferably O. Hexapeptides may be based on any of the preferred tripeptides, C-B-A, set out above, extended at their C-termini by amino acids within the definitions D, E and F. A wide variety of X groups is possible, but -OH, acylsulphonamide, -H and $-CO_2H$ are preferred. Relatively small Z groups are preferred. In particular, Z together with its adjacent NH group may form a lower alkyl amide group.

Preferred hexapeptides



include:



and



Examples of hexapeptides of the first aspect of the invention can be found at Table 1.

In a second aspect, the invention is particularly concerned with molecules of formula:

Y-B-A'-X' (FORMULA II)

where the groups Y and B are as defined above and X' is -OH, or $-NHSO_2R_{25}$, where R_{25} is as defined above, and pharmaceutically acceptable salts and esters thereof.

A' is a naturally, or non-naturally occurring amino acid residue of formula



wherein m is 0, or 1 (preferably 0) and R_1 is a fluorine-substituted hydrocarbyl side chain. The hydrocarbyl side chain may be an alkyl, alkenyl, aralkyl, or aryl group having from 1 to 15, preferably 2 to 10, particularly 2 to 8 carbon atoms. The side chain preferably includes at least one, more preferably at least two, fluorine atoms at the position γ- to the carbonyl group of the amino acid including the fluorinated side chain.

Examples of suitable side chains are:

Of these,



is particularly preferred.

As with the compounds of the first aspect of the invention each naturally or non-naturally occurring amino acid, (A-F) may have D- or L-stereochemistry, but L-stereochemistry is generally preferred. However, either

D- or L-stereochemistry is allowed at amino acid A, although in general the L isomer is preferred. Particularly preferably all the naturally or non-naturally occurring amino acid residues in the peptides of this aspect of the invention are L-isomers.

Compounds of this aspect of the invention may be substantially pure single stereoisomers, or may be mixtures of stereoisomers, especially of diastereoisomers having different stereochemistry at the A amino acid only.

Particularly preferred molecules of this aspect of the invention are hexapeptides. For example, the following formulae show preferred hexapeptides of the second aspect of the invention:



and



where Z is as defined above for the first aspect, and is preferably an acyl group, for example an acetyl group and R_1 is a fluorinated hydrocarbon side chain having from 1 to 15, preferably 2 to 10, particularly 2 to 8 carbon atoms.

Examples of hexapeptides of the second aspect of the invention are included in Table 1 (see compounds 1a, 1b, 1g, and 1h).

Compounds of the first and second aspects of the invention typically inhibit the action of HCV NS3 protease at concentrations (IC_{50}s) of 100μM and below. The longer peptides are generally inhibitory at lower concentrations than the shorter ones because of their greater potential for enzyme binding. However, the activities of the shorter peptides are surprisingly high.

Examples of the hexapeptides of the invention are typically inhibitory at concentrations of 10μM or below. Some are inhibitory at concentrations of 5μM or below, or even at 1μM or below.

Examples of the tripeptides and tetrapeptides of the invention are typically inhibitory at concentrations of 20μM or below, preferably 10μM or below, particularly 5μM or below. Optimised tripeptides may be effective at concentrations below 1μM.

Examples of the dipeptides of the invention are effective at concentrations of 50μM or less, preferably 30μM or less, especially 10μM or less.

Embodiments of the first and second aspect can therefore be expected to be of use in the treatment and prevention

of hepatitis C and other related conditions.

According to a third aspect of the invention there are provided derivatives of the compounds of the first or second aspect of the invention.

In particular, derivatives include "prodrug" forms of the compounds of Formula I or Formula II which may be converted in vivo into the compound of Formula I or II. Examples of such derivatives include those in which one or more carboxylic acid groups of the compound of Formula I or II are esterified or otherwise derivatised into groups convertible in vivo into carboxylic acid or carboxylate groups. For instance carboxylic acid groups may be esterified with C_1-C_{18} alcohols, preferably C_1-C_8 alcohols. Another possibility is that the derivative may be a C-terminal extended variant of the compound of Formula I or II, convertible in vivo into a compound of Formula I or II.

According to a fourth aspect the present invention provides a compound or derivative according to the first, second or third aspect, for use in any therapeutic method, preferably for use in inhibiting the HCV NS3 protease, and/or for use in treating or preventing hepatitis C or a related condition. By "related condition" is meant a condition which is or can be caused, directly or indirectly, by the hepatitis C virus, or with which the HCV is in any way associated.

According to a fifth aspect the present invention provides the use of a compound or derivative according to the first, second or third aspect in the manufacture of a medicament for the treatment or prevention of hepatitis C or a related condition.

A sixth aspect of the invention provides a pharmaceutical composition which includes one or more compounds or derivatives according to the first, second, or third aspect.

The composition may also include pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers and other excipients. It may additionally include other therapeutically active agents, in particular those of use in treating or preventing hepatitis C or related conditions.

The pharmaceutical composition may be in any suitable form, depending on the intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally.

According to a seventh aspect of the invention, there is provided a method of inhibiting HCV NS3 protease activity, and/or of treating or preventing hepatitis C or a related condition, the method involving administering to a human or animal (preferably mammalian) subject, e.g. one suffering from the condition, a therapeutically or prophylactically effective amount of a composition according to the sixth aspect of the invention, or of a compound or derivative according to the first aspect. "Effective amount" means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject's condition.

The dosage rate at which the compound, derivative or composition is administered will depend on the nature of the subject, the nature and severity of the condition, the administration method used, etc. Appropriate values

can be selected by the trained medical practitioner. Preferred daily doses of the compounds are likely to be of the order of about 1 to 100 mg. The compound, derivative or composition may be administered alone or in combination with other treatments, either simultaneously or sequentially. It may be administered by any suitable route, including orally, intravenously, cutaneously, subcutaneously, etc. Intravenous administration is preferred. It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell - suitable targeting methods are already known.

An eighth aspect of the invention provides a method of preparation of a pharmaceutical composition, involving admixing one or more compounds or derivatives according to the first, second or third aspect of the invention with one or more pharmaceutically acceptable adjuvants, and/or with one or more other therapeutically or prophylactically active agents.

The compounds themselves may be prepared by reacting a compound of formula $Y\text{-}NH\text{-}CHR_2\text{-}CO_2H$, optionally in a protected form, with an appropriate amine co-reactant (depending on the intended nature of R_1 and X in the final compound), examples of which include:



FORMULA K

(for X = OH, as in compounds 1a, 1b, 1g and 1h in Table 1 infra), R' being a protecting group;



FORMULA L

(for X = H, or a functional group other than OH eg, as in compounds 1c, 1d, 1e, 1f, 1i 1j, 1k, 1l, 1m, 1n or 1o in Table 1 infra), R^v corresponding to, or being convertible into the functional group, X; and



FORMULA M

(for X = H, as in compound 1c, R" being a lower alkyl group such as methyl or ethyl).

Compounds of formula I or II having m=1 may be produced using homologs of the above compounds of formulae K, L and M including an additional CH_2 group at the appropriate position which is indicated by brackets in the formulae, and also in formula N below. However, since elongating the chain in P1 may lead to significant loss of activity it is preferred that m=0.

Compounds of formulae K, L and M may be used as racemates or, alternatively, as individual D- or L-isomers. When a racemate is used subsequent separation of product diastereomers may be desirable.

In each case, the reaction can be carried out using standard methods of peptide synthesis. In the case of formula L, oxidation of the hydroxyl to a carbonyl group is also needed. In all cases, protecting groups may need to be removed, for instance under mildly acidic or basic conditions, to reach the final product.

A preferred compound of formula K is racemic 4,4-difluoro-2-aminobutyric acid. One possible scheme for the preparation of this compound is set out below in scheme 1

Scheme 1[a]



[a]Reagents: (a) Tf_2O, CH_2Cl_2, Et_3N; (b) KO^tBu, THF, Δ; (c) 6 N HCl, reflux

The individual R- and S- enantiomers of 4,4-difluoro-2-aminobutyric acid may be prepared from D- and L- aspartic acid, respectively using the method described by Winkler et al in Synthesis (1996), 1419-1421. The carboxylic acid group of these compounds may be protected, for instance by formation of t-butyl esters as shown below in scheme 2

Scheme 2[a]



[a]Reagents: (a) CbzOSu, Na_2CO_3, dioxane; (b) isourea, CH_2Cl_2; (c) H_2, Pd/C, ether/HCl

One example of a racemic diacetal of formula M may be prepared as outlined below in scheme 3 which begins with racemic 4,4-difluoro-2-aminobutyric acid.

Scheme 3[a]



[a]Reagents: (a) Boc_2O; (b) NH(OMe)Me•HCl, EDC, HOBt, iPr_2NEt;
(c) Dibal, THF, -78 °C; (d) $HC(OMe)_3$, TsOH; (e) HCl (gas), MeOH

One example of a compound of formula L, which is particularly suitable for the production of compounds in which X is a ketoacid group is that of formula L' below



FORMULA L'

where R''' is a protecting group for carboxylic acids, such as a lower alkyl group. The compound is optionally in the form of its acid addition salt.

A particularly preferred example of such a compound is



This may be prepared according to the scheme set out below at Scheme 4.

Scheme 5 below shows one example of how this compound may be reacted with a tripeptide to form a tetrapeptide. The same procedure could be employed to make other oligopeptides of the invention.

Scheme 4[a]



[a]Reagents: (a) Boc_2O; (b) Ph_3P=CHCN, EDC, DMAP; (c) O_3, CH_2Cl_2, MeOH, -78° C; $NaBH_4$, MeOH; (d) HCl, EtOAc; (e) CbzOSu, Na_2CO_3, dioxane; (f) Ph_3P=CHCN, EDC, HOBt, CH_2Cl_2; (g) Pd/C, NH_4HCO_2, MeOH

Scheme 5[a]



2a

[a]Reagents: (a) HATU, DMF, 2,6-lutidine; (b) Dess-Martin periodinane, CH_2Cl_2; (c) TFA, CH_2Cl_2, H_2O; (d) 1 N NaOH, MeOH; (e) RP-HPLC

An alternative intermediate for the production of compounds having ketoacid functionally at X is a phosphorane based precursor which has the formula shown below:



FORMULA N

and the production of a preferred example of such a compound:



FORMULA N'

is also shown in Scheme 4.

These compounds may be reacted with optionally protected compounds of formula $Y\text{-}NH\text{-}CHR_2\text{-}CO_2H$ to form certain compounds of the present invention.

The use of the phosphorane based precursor is demonstrated in Scheme 6 with the synthesis of the tripeptide keto acids 3c and 5j and the capped dipeptide keto acid 71. The same reagents and reaction conditions may be used in the production of other oligopeptides of

the invention.

Scheme 6[a]



[a]Reagents: (a) EDC, HOBt, CH_2Cl_2; (b) O_3, -78 °C, CH_2Cl_2/MeOH; (c) 1 N NaOH, MeOH; (d) RP-HPLC; (e) Pd/C, NH_4HCO_2; (f) EDC, HOBt, CH_2Cl_2, BocGlu(OBn)OH; (g) O_3, -78 °C, CH_2Cl_2; THF, H_2O; (h) CH_2Cl_2, *i*-Pr_2NEt;

Scheme 7 shows the synthesis of the indoline keto acid inhibitor 9y. Analogous methods may be employed for production of the other indoline keto acids.

Scheme 7[a]



[a]Reagents: [a]Reagents: (a) EDC, HOBt, CH_2Cl_2; (b) O_3, -78 °C, CH_2Cl_2/MeOH; (c) $NaBH_4$, MeOH; (d) HCl, dioxane/EtOAc; (e) Boc_2O, NEt_3, MeOH: (f) BnBr, Cs_2CO_3, DMF, r.t.; (g) KHMDS, RBr, THF, -78°C → r.t.; (h) H_2, Pd/C, MeOH; (i) HATU, DIPEA, CH_2Cl_2/DMF (1:1); (k) DMP, CH_2Cl_2, tBuOH; (l) TFA, CH_2Cl_2, H_2O, TES; (m) 1 N NaOH, MeOH; (n) RP-HPLC.

Compounds of formula Y-NH-CHR_2-CO_2H may be generated wholly or partly by chemical synthesis, and in particular can be prepared according to known peptide synthesis methods.

Preferably, the compound of formula Y-NH-CHR_2-CO_2H for reaction with a compound of formula K, L, M or N will be

in protected form. For instance, any carboxylic acid groups other than that at the C terminus may preferably be protected, for instance as esters, eg as tertiary butyl esters. Examples of two highly preferred protected pentapeptides suitable for use in synthesis of hexapeptides of the present invention are set out below and labelled (P) and (Q)



(P)



(Q)

The invention provides, according to a ninth aspect, a method as described above for preparing a compound according to the first or second aspect of the invention.

Examples

Embodiments of the invention are described below by way of example only.

The following abbreviations are used herein:

Bn	benzyl
CbzOSu	N-(Benzyloxycarbonyloxy)succinimide
Dibal	Diisobutylaluminum hydride
DIPEA	Diisopropylethyl amine
DMAP	4-Dimethylaminopyridine
DMF	Dimethylformamide
DMP	Dess Martin periodinane
EDC	1-Ethyl-3-(3'dimethylaminopropyl)carbodiimide hydrochloride
HATU	O-(&-Azabenzotriazol-1-yl)-N,N,N'N'-tetramethyluronium hexafluorophosphate
HOBt	N-Hydroxybenzotriazole
KHMDS	Potassium bis(trimethylsily)amide
TES	Triethylsilane
Tf_2O	Trifluoromethanesulfonic anhydride
THF	Tetrahydrofuran

(1) Synthesis

HPLC Conditions: Reversed phase analytical HPLC was performed on a Waters Symmetry C18 column (150 x 3.9 mm, 5 µm), flow rate 1 mL/min, using H_2O/0.1% TFA (A) and CH_3CN/0.1% TFA (B) as eluents; detection at 220 nm with a Waters 996 PDA detector. Gradient 1: linear, 90 A- 20% A 8 min, then in 2 min to 0% A, then isocratic. Gradient 2: linear, 70 - 40% A 10 min. . Gradient 3: linear, 90 - 70% A 10 min. Preparative HPLC was conducted on a Waters Symmetry C18 column (150 x 19 mm, 7µm) or a Waters Prep Nova-Pak HR C18 cartridge (40 x 100 mm, 6 µm) using H_2O/0.1% TFA (A) and CH_3CN/0.1% TFA (B) as eluents;

detection at 220 nm with a Waters 486 absorbance detector.

EXAMPLE 1: Synthesis of compound 1a

i) *(S)*-tert-Butyl-2-amino-4,4-difluoro butanoate hydrochloride

Using the procedure described in example 3 (i) for the (R)-enantiomer, the title compound was obtained as an off-white powder; mp 152 - 153 °C (MeOH, Et_2O, pentane); α_D +5.1° (c = 1.0, anhydrous MeOH). ^{1}H-NMR (DMSO-d_6) δ 1.44 (s, 9 H), 2.36 - 2.50 (m, 2 H), 4.05 (bs, 1 H), 6.31 (tt, *J* = 4.5, 55.6 Hz, 1 H), 8.71 (bs, 3H); ^{13}C-NMR (DMSO-d_6) δ 27.3, 34.3 (t, *J* = 23.3 Hz), 47.6, 83.5, 114.9 (t, *J* = 238 Hz), 167.1; ^{19}F-NMR (DMSO-d_6) δ -114.4 (d, *J* = 285 Hz), -115.2 (d, *J* = 285 Hz); MS *m/z* 196 (M^+ + H).

ii) (1a)

The protected pentapeptide shown below (ac-tert-butyl-asp-tert-butyl-glu-met-tert-butyl-glu-tert-butyl-glu) was employed in this example



30 mg pentapetide (0.03 mmol) was dissolved in dichloromethane (0.5 mL) and cooled to 0 °C. N-Ethyl, N'-(dimethylamino)propylcarbodiimide hydrochloride (EDC) (6.3 mg, 0.033 mmol) and hydroxybenzotriazole (HOBT) (4.9 mg, 0.036 mmol) were added, followed by solid (S)-tert-butyl-2-amino-4,4-difluoro-butanoate hydrochloride (from i, above) (10.4 mg, 0.045 mmol) and diisopropylethylamine (0.01 mL, 0.06 mmol). The resulting solution was stirred

overnight at room temperature, then taken into ethyl acetate (50 mL) and washed successively with 1 N HCl (2x 25 mL), saturated aqueous $NaHCO_3$ (2 x 20 mL), and brine. Drying (Na_2SO_4) and evaporation gave a solid which was immediately treated with a solution of trifluoroacetic acid, dichloromethane and water (60/30/10, v/v/v; 10 mL). After 30 min at room temperature the solvents were evaporated in vacuo and the remaining solid separated by preparative HPLC (Waters Symmetry column). Flow 17 mL/min; Gradient : linear, 90% A, 3 min isocratic, in 15 min to 75% A; 7 mg of crude per injection. The product, compound 1a (RT 10.4 min), 12 mg (50%), was obtained as a colourless solid after lyophilization.

^{1}H-NMR (DMSO-d_6) δ 1.73 - 1.95 (m, 8 H), 1.83 (s, 3 H), 2.02 (s, 3 H), 2.19 - 2.30 (m, 8 H), 2.35 -2.48 (m, 3 H), 2.61 (dd, J = 5.2, 11.7 Hz, 1 H), 4.14 - 4.26 (m, 3 H), 4.29 (m, 1 H), 4.36 (m, 1 H), 4.50 (dd, J = 5.4, 7.7 Hz, 1 H), 6.05 (ddt, J = 4.6, 51.6 Hz, 1 H), 7.92 (d, 1 H, J = 8.4 Hz, 1 H), 7.96 (d, 1 H, J = 8.2 Hz, 1 H), 7.99 (m, 2 H),), 8.18 (d, 1 H, J = 7.5 Hz, 1 H), 8.33 (bd, 1 H, J = 7.0 Hz, 1 H), 11.9 - 12.4 (bs, 5 H); ^{19}F-NMR (DMSO-d_6) δ -115.0 (d, J = 282 Hz), -115.8 (d, J = 284 Hz); MS m/z 815 (M^+ + H).

EXAMPLE 2: Synthesis of compound 1b[1]

In this example, (S)-tert-butyl-2-amino-4,4-difluoro-butanoate hydrochloride (prepared as described in example 1, i)) was used in the preparation of the first diastereomer of compound 1b.

This example, and also examples 3, 4 and 5 below, employed the protected pentapeptide shown below (Ac-tert-butyl-asp-tert-butyl-glu-diphenylala-tert-butyl glu-cyclohexyl-ala)



i) ($\underline{1b^1}$)

50 mg pentapetide (0.05 mmol) was dissolved in DMF (0.5 mL) and cooled to 0 °C. HATU and solid (S)-tert-butyl-2-amino-4,4-difluoro-butanoate hydrochloride were added, followed by 2,6-lutidine (0.024 mL, 0.2 mmol). The reaction was allowed to reach room temperature and stirred for 3 h. Analytical HPLC (gradient 1) indicated incomplete conversion of the pentapeptide (~30% remaining, RT 10.4 min, gradient 1, product 11.9 min). After another 2 h the mixture was taken into ethyl acetate (100 mL) and washed successively with 1 N HCl, (2x 50 mL), saturated aqueous $NaHCO_3$ (2 x 50 mL), and brine. Drying with sodium sulfate and evaporation gave a light yellow solid which was immediately deprotected with a solution of trifluoroacetic acid, dichloromethane and water (60/30/10, v/v/v; 10 mL). After 30 min at room temperature the solvents were evaporated in vacuo and the remaining solid separated by preparative HPLC (Waters Symmetry column). Flow 17 mL/min; Gradient : linear, 68% A, 3 min isocratic, in 17 min to 65% A; 6 mg of crude per injection. The first peak was deprotected pentapetide (RT 11.6 min), the second the desired product compound 1b (RT 12.2 min); 11 mg (23%) of a colourless solid after lyophilization.

^{1}H-NMR (DMSO-d_6) δ 0.76-0.95 (m, 2 H), 1.08 - 1.32 (m, 4 H), 1.32 - 1.41 (m, 1 H), 1.42 - 1.51 (m, 1 H), 1.53-1.80 (m, 9 H), 1.83 (s, 3 H), 1.97 - 2.35 (m, 6 H), 2.38 - 2.50 (m, 2 H), 4.04 - 4.13 (m, 2 H), 4.13 - 4.21 (m, 1 H), 4.27 - 4.37 (m, 1 H), 4.38 (d, J = 10.3 Hz, 1 H), 4.47 (m, 1 H), 5.19 (app. t, J = 9.5 Hz, 1 H), 6.04 (ddt,

J = 4.0, 5.7, 56.2 Hz, 1 H), 7.05-7.33 (m, 10 H), 7.75 (d, 1 H, J = 7.3 Hz, 1 H), 7.79 (d, 1 H, J = 8.0 Hz, 1 H), 7.89 (d, 1 H, J = 8.1 Hz, 1 H),), 7.96 (d, 1 H, J = 7.6 Hz, 1 H), 8.10 (d, 1 H, J = 7.0 Hz, 1 H), 8.10 -8.12 (bs, 1 H); MS m/z 929 (M^+ - H).

EXAMPLE 3: Synthesis of compound 1b[2]

i) (*R*)-tert.-Butyl-2-amino-4,4-difluoro-butanoate hydrochloride

1.5 g (10.78 mmol) of (*R*) 2-Amino-4,4-difluoro butanoic acid (prepared as described in Winkler et al, Synthesis 1419, 1996) was dissolved in aqueous half saturated Na_2CO_3 (50 mL) and cooled to 0 °C. A solution of (benzyloxy-carbonyloxy)succinimide (2.69 g, 10.78 mmol) in dioxane (50 mL) was added dropwise over 30 min. The resulting suspension was stirred overnight at room temperature. After evaporation of the dioxane under reduced pressure, water (20 mL) and EtOAc (150 mL) were added. The aqueous phase was brought to pH 2 by addition of 1 N HCl, the organic phase was separated, washed with brine and dried. Evaporation gave 2.85 g (97%) of a colourless oil.

This material (950 mg; 3.55 mmol) was dissolved in dichloromethane (15 mL) and N,N'-isopropyl-O-tert-butyl isourea (1.42 g, 7.10 mmol) was added dropwise. The solution was brought to gentle reflux. After 8 h another 1.42 g of the isourea was added and reflux was continued overnight. The diisopropylurea was removed by filtration, and the residue purified by flash chromatography (petroleum ether/ethyl acetate 10 : 1) to give a colourless oil (844 mg; 72%). ^{1}H-NMR (DMSO-d_6) δ 1.38 (s, 9 H), 2.14 - 2.28 (m, 2 H), 4.08 (m, 1 H), 5.03 (d, J = 12.6 Hz, 1 H),), 5.06 (d, J = 12.6 Hz, 1 H), 6.10 (tt, J = 4.7, 56.2 Hz, 1 H), 7.27 - 7.39 (m, 5 H), 7.79 (d, J = 8.1 Hz, 1 H); ^{13}C-NMR (DMSO-d_6) δ 27.4, 34.9 (t, J = 22.5

Hz), 49.5, 65.5, 81.2, 115.9 (t, J = 238 Hz), 127.7, 127.8, 128.3, 136.7, 155.8, 169.8; ^{19}F-NMR (DMSO-d_6) δ -115.1 (d, J = 283 Hz), -115.8 (d, J = 283 Hz); MS m/z 330 (M^+ + H).

300 mg (0.91 mmol) of this material were hydrogenated over 10% palladium-on-charcoal in methanol (10 mL). After 5h, the catalyst was removed by filtration, then some ethyl acetate and a 1 N solution of hydrochloric acid in diethyl ether (1.37 mL) were added. After evaporation in vacuo the title compound (203 mg; 96%) was obtained as an off-white solid; mp 153 - 154 °C; ^{1}H-NMR (DMSO) δ 1.44 (s, 9 H), 2.38 - 2.50 (m, 2 H), 4.03 (t, J = 6.2 Hz, 1 H), 6.35 (tt, J = 4.3, 55.6 Hz, 1 H), 8.85 (bs, 3H); ^{13}C-NMR (DMSO-d_6) δ 27.3, 34.3 (t, J = 23.3 Hz), 47.6, 83.4, 114.9 (t, J = 238 Hz), 167.0; ^{19}F-NMR (DMSO-d_6) δ -114.5 (d, J = 285 Hz), -115.3 (d, J = 285 Hz); MS m/z 196 (M^+ + H).

ii) (1b^2)

The method for the coupling is described in example 2, i).

After 3 h analytical HPLC indicated only minor amounts of the protected pentapeptide. After workup the crude product was deprotected as described in example 2 and separated by preparative HPLC (Waters Symmetry column). Flow 17 mL/min; Gradient : linear, 70% A, 3 min isocratic, in 12 min to 40% A; 6 mg of crude per injection. 22 mg (47%) of 17 (RT 9.2 min) as a colourless solid were obtained after lyophilization.

^{1}H-NMR (DMSO-d_6) δ 0.77-0.91 (m, 2 H), 1.06 - 1.25 (m, 4 H), 1.29 - 1.36 (m, 1 H), 1.37 - 1.44 (m, 1 H), 1.52-1.80 (m, 9 H), 1.82 (s, 3 H), 1.99 - 2.13 (m, 4 H), 2.16 - 2.33 (m, 2 H), 2.42 (dd, J = 8.8, 16.6 Hz, 1 H), 2.49 (under DMSO, m, 1 H), 4.08 (m, 2 H), 4.21 (m, 1 H), 4.33 (m, 1 H), 4.37 (d, J = 10.3 Hz, 1 H), 4.47 (m, 1 H), 5.21

(app. t, J = 9.4 Hz, 1 H), 5.99 (dt, J = 4.6, 56.3 Hz, 1 H), 7.05-7.40 (m, 10 H), 7.65 (d, 1 H, J = 7.7 Hz, 1 H), 7.78 (d, 1 H, J = 7.9 Hz, 1 H), 7.87 (d, 1 H, J = 8.4 Hz, 1 H),), 7.96 (d, 1 H, J = 7.8 Hz, 1 H), 8.14 (d, 1 H, J = 7.7 Hz, 1 H), 8.30 (d, 1 H, J = 8.10 Hz, 1 H), 11.90 - 12.30 (bs, 4 H); MS m/z 929 (M^+ - H).

EXAMPLE 4: Synthesis of compound 1c

i) 1,1-Difluoro-2-trifluoromethanesulfonyloxyethane

Triflic anhydride (120 g, 0.427 mol) was dissolved in anhydrous dichloromethane (70 mL) and cooled to -60% C. A solution of triethylamine (59.5 mL, 0.427 mol) and difluoroethanol (35 g, 0.427 mol) in dichloromethane (70 mL) was added slowly, so that the internal temperature did not exceed -50% C. After complete addition the resulting yellow solution was allowed to reach room temperature. Dichloromethane was distilled off under atmospheric pressure, and the remaining liquid fractionally distilled under reduced pressure (70 - 80 mbar), using a 20 cm Vigreux column to give the title sulfonate (86.2 g, 94%) (b.p.: 58 - 60 °C). ^{1}H-NMR ($CDCl_3$) δ 4.58 (dt, J = 3.6, 12.8 Hz, 2 H), 6.05 (tt, J = 3.6, 54 Hz, 1 H); ^{19}F- NMR ($CDCl_3$) δ -74.6 (s), -127 (s).

ii) Diethylacetamido-2-(2',2'-difluoroethyl) malonate

Diethyl acetamido malonate (35.8 g, 0.165 mol) was dissolved in anhydrous THF (300 mL) and treated with potassium tert-butanolate (18.5 g, 0.165 mol) under vigorous stirring. The resulting suspension was refluxed for 1.5 h, and the above sulfonate (40 g, 0.187 mol) was added carefully *via* syringe to the refluxing suspension. The solution became homogeneous and was refluxed for another 3h. The solution was concentrated, and the residue dissolved in ethyl acetate and washed with

hydrochloric acid (0.5 N, 2x), water (2x), saturated aqueous $NaHCO_3$, sodium hydroxide (1 N, 1x) and brine. Drying (Na_2SO_4) and evaporation left an orange oil, which was dissolved in diethyl ether (250 mL). The flask was kept at -20 °C overnight. 32.6 g (70%) of a colourless solid was collected; mp 72 - 73 °C. ^{1}H-NMR ($CDCl_3$) δ 1.26 (t, *J* = 7.1 Hz, 6 H), 2.05 (s, 3 H), 2.98 (dt, *J* = 4.7, 16.5 Hz, 2 H), 4.27 (q, *J* = 7.1 Hz, 4 H), 5.85 (tt, *J* = 4.7, 55.8 Hz, 1 H), 6.90 (bs, 1 H); ^{13}C-NMR ($CDCl_3$) δ 13.8, 22.9, 36.8 (t, *J* = 22.6 Hz), 62.8, 63.1, 115.2 (t, *J* = 239 Hz), 167.0, 169.7; ^{19}F-NMR ($CDCl_3$) δ -116.8 (s); MS *m/z* 282 (M^+ + H).

iii) *(R,S)*-2-Amino-4,4-difluorobutanoic acid hydrochloride

The malonate prepared above (32 g, 0.114 mol) was refluxed in 500 mL hydrochloric acid (6 N) overnight. The aqueous phase was extracted with diethyl ether and then evaporated to give the title compound (19.9 g; quantitative yield) as a colourless solid; mp 164 - 165 °C. ^{1}H-NMR (D_2O) δ 2.35 - 2.70 (m, 2 H), 4.27 (dd, *J* = Hz, 1 H), 6.19 (tt, *J* = Hz, 1 H); ^{13}C-NMR (D_2O) δ 34.0 (t, *J* = 22.2 Hz), 48.2, 115.7 (t, *J* = 238 Hz), 171.4; ^{19}F-NMR (D_2O) δ -112.7 (d, 287 Hz), -114.2 (d, 287 Hz); MS *m/z* 149 (M^+ + H).

iv) *(R,S)*-(2-N-(tert-Butoxycarbonyl)-amino)-4,4-difluoro-butyric N-methyl-O-methylcarboxamide

1.0 g (5.7 mmol) of *(R,S)*-2-amino-4,4-difluoro butanoic acid hydrochloride was converted to its Boc derivative using di-tert.-butyl dicarbonate (1.24 g, 5.7 mmol). After extractive workup 1.16 g (85%) of a colourless solid was obtained, which was used without further purification; mp 127 - 129 °C. ^{1}H-NMR (DMSO-d_6) δ 1.37 (s, 9 H), 2.15 (m, 2 H), 4.03 (m, 1 H), 6.07 (tt, *J* = 4.5, 56 Hz, 1 H), 7.30 (d, *J* = 8.5 Hz, 1 H), 12.80 (bs, 1 H); ^{13}C-

NMR (DMSO-d_6) δ 28.0, 35.0 (t, J = 22 Hz), 48.4, 78.3, 116.0 (t, J = 238 Hz), 155.3, 172.5; ^{19}F-NMR (DMSO-d_6) δ -115.0 (d, J = 282 Hz), -115.7 (d, J = 282 Hz); MS m/z 240 (M^+ + H).

To a solution of the Boc derivative prepared above (1.59 g, 6.65 mmol), EDC (1.40 g, 7.32 mmol) and HOBt (1.08 g, 7.98 mmol) in anhydrous dichloromethane (30 mL) was added a solution of N,O-dimethylhydroxylamine hydrochloride (714 mg, 7.32 mmol) and diisopropylethylamine (1.74 mL, 9.98 mmol) in dichloromethane (20 mL) at 0 °C. After stirring at room temperature for 3 days, some dichloromethane was removed under reduced pressure. The resulting solution was diluted with ethyl acetate (150 mL) and washed successively with 1 N HCl (2x), sat. aqueous $NaHCO_3$ (2x) and brine. The organic extract was dried (Na_2SO_4) and concentrated in vacuo to give the title compound (1.81 g; 96%) of as a colourless solid. A small sample was recrystallized for analytical purposes: mp 81 -82 °C. ^{1}H-NMR ($CDCl_3$) δ 1.44 (s, 9 H), 1.93 - 2.44 (m, 2 H), 3.23 (s, 3 H), 3.76 (s, 3 H), 4.84 (m, 1 H), 5.39 (bd, J = 9.0 Hz, 1 H), 5.95 (ddt, J = 3.6, 5.8, 56.0 Hz, 1 H); ^{13}C-NMR ($CDCl_3$) δ 28.3, 32.3, 37.6 (t, J = 22 Hz), 46.3, 61.7, 80.2, 115.3 (t, J = 239 Hz), 155.3, 171.2; ^{19}F-NMR ($CDCl_3$) δ -114.6 (d, J = 287 Hz), -115.5 (d, J = 287 Hz); MS m/z 283 (M^+ + H).

(v) <u>(*R,S*)-2-(N-tert.-Butoxycarbonyl)amino-4,4-difluorobutyraldehyde dimethylacetal</u>

To a solution of the above compound (4.89 g, 17.32 mmol) in tetrahydrofuran (100 mL) was added neat diisobutylaluminum hydride (6.79 mL, 38.11 mmol) dropwise at -78 °C. The solution was stirred for 2.5 h at this temperature, then methanol (5 mL) was added dropwise and the cooling bath removed. The solution was diluted with ethyl acetate (500 mL) and then washed successively with ice-cold 1 N HCl (150 mL, 3x), 2 N aqueous Rochelle's

salt (150 mL) and brine (2x). Drying of the organic extract (Na_2SO_4) and evaporation in vacuo gave 3.47 g (90%) of (*R,S*)-2-(N-tert.-Butoxy carbonyl)-amino-4,4-difluoro butyraldehyde as an opaque oil, which was used in the next step without further purification. ^{1}H-NMR ($CDCl_3$) δ 1.47 (s, 9 H), 2.25 (m, 1 H), 2.55 (m, 1 H), 4.31 (m, 1 H), 5.33 (bs, 1 H), 6.03 (dt, *J* = 6.0, 56 Hz, 1 H), 9.60 (s, 1 H).

1.8 g (8.06 mmol) of the crude aldehyde were converted into the dimethylacetal using trimethylorthoformate (12.4 mL, 112.9 mmol) and p-toluenesulfonic acid (154 mg, 0.81 mmol) in anhydrous methanol (30 mL). After stirring overnight at room temperature, TLC (petrolether/ethyl acetate 2:1) indicated complete consumption of the aldehyde. Saturated aqueous $NaHCO_3$ was added and the methanol evaporated under reduced pressure. The residue was dissolved with ethyl acetate (200 mL) and washed successively with saturated aqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation left an oil which was purified by flash chromatography (160 g silica gel, petrolether/ethyl acetate 4 : 1, containing 0.5% triethylamine), to give the title compound (1.44 g; 66%) as a colourless solid; mp 61 -62 °C. ^{1}H-NMR ($CDCl_3$) δ 1.48 (s, 9 H), 1.86 - 2.05 (m, 1 H), 2.09 - 2.27 (m, 1 H), 3.44 (s, 3 H), 3.45 (s, 3 H), 3.99 (m, 1 H), 4.25 (d, *J* = 3.0 Hz, 1 H), 4.76 (bd, *J* = 8.0 Hz, 1 H), 5.96 (ddt, *J* = 4.0, 5.4, 56.6 Hz, 1 H); ^{13}C-NMR ($CDCl_3$) δ 28.3, 34.4 (t, *J* = 22 Hz), 47.6, 55.9, 56.5, 79.8, 105.6, 116.3 (t, *J* = 238 Hz), 155.5; ^{19}F-NMR ($CDCl_3$) δ -114.6 (d, *J* = 284 Hz), -115.5 (d, *J* = 284 Hz); MS *m/z* 270 (M^+ + H).

vi) <u>(*R,S*)-2-Amino-4,4-difluorobutyraldehyde dimethylacetal hydrochloride</u>

To 440 mg (1.63 mmol) of the above acetal was added a solution of gaseous HCl in anhydrous methanol (10% HCl by weight, 15 mL) at 0 °C. The solution was stirred at this

temperature for 10 min, then the ice-bath was removed. After 20 min at ambient temperature TLC indicated complete consumption of the acetal to baseline material. The reaction mixture was evaporated to dryness, then trituated with n-pentane. Drying under high vacuum produced 310 mg (93%) of **13** an light brown hygroscopic solid, which was pure by ^{1}H-NMR (400 MHz) and used without further purification. ^{1}H-NMR (DMSO-d_6) δ 2.13 - 2.23 (m, 2 H), 3.32 - 3.37 (m, 1 H), 3.40 (s, 3 H), 3.41 (s, 3 H), 4.56 (d, J = 4.7 Hz, 1 H), 6.33 (tt, J = 4.8, 56.2 Hz, 1 H), 8.45 (bs, 3 H); ^{13}C-NMR (DMSO-d_6) δ 32.6 (t, J = 22.6 Hz), 47.0, 55.8, 55.9, 102.8, 115.5 (t, J = 235.3 Hz); ^{19}F-NMR (DMSO-d_6) δ -113.8 (d, J = 283 Hz), -114.7 (d, J = 283 Hz); MS m/z 206 (M^+ + H).

vii) (1c)

220 mg of the protected pentapeptide (Ac-tert-butyl-asp-tert-butyl-glu-diphenylalanine-tert-butyl-glu-cyclohexylala) (0.225 mmol) were dissolved in 1 mL chloroform. EDC (52 mg, 0.27 mmol) and HOBt (61 mg, 0.45 mmol) were added and the solution cooled to 0 °C. (± 2-Amino-4,4-difluorobutyraldehyde dimethylacetal hydrochloride (from vi above) (80 mg, 0.39 mmol) was dissolved in chloroform (0.8 mL) containing diisopropylethyl amine (0.47 mmol, 0.082 mL) and the resulting solution was added via syringe to the pentapeptide. Another 0.3 mL chloroform was used to rinse flask and syringe. The cooling bath was removed after 10 min and the orange solution stirred for 3 h. Analytical HPLC indicated complete conversion of the pentapetide. The reaction was taken into a mixture of ethyl acetate and dichloromethane (150 mL, 3 : 1) and washed successively with 0.1 M aqueous $KHSO_4$, (3x 80 mL), water (2x 100 mL), saturated aqueous $NaHCO_3$ and brine (2x 100 mL). Drying (Na_2SO_4) and evaporation gave a brown solid which was immediately deprotected with a solution of trifluoroacetic acid, dichloromethane and water (60/35/5,

v/v/v; 50 mL). After 30 min at room temperature the solvents were evaporated in vacuo and the remaining brown solid (252 mg) was separated by preparative HPLC (Nova-Pak Prep column). Flow 40 mL/min; Gradient : linear, 70% A, 2 min isocratic, in 18 min to 60% A; 20 mg of crude per injection.

First fraction: RT: 9.4 min, 54 mg (26%) of a colourless powder after lyophilization; 1 diastereomer, 94% pure by analytical HPLC (gradient 1, 6.77 min; gradient 2, 6.45 min). In the ^{1}H-NMR 10 - 20% of the aldehyde was hydrated. Addition of water gave a ratio of aldehyde to hydrate of 1 : 9. Only data for the aldehyde are reported. ^{1}H-NMR (DMSO-d_6) δ 0.77 - 0.94 (m, 2 H), 1.05 - 1.31 (m, 4 H), 1.32 - 1.50 (m, 2 H), 1.52 - 1.78 (m, 9 H), 1.82 (s, 3 H), 1.95 - 2.15 (m, 6 H), 2.36 - 2.46 (m, 2 H), 4.00 - 4.06 (m, 2 H),), 4.12 - 4.23 (m, 2 H), 4.39 (d, J = 10.3 Hz, 1 H), 4.47 (m, 1 H), 5.19 (app. t, J = 9.4 Hz, 1 H), 6.10 (dt, J = 4.6, 56.0 Hz, 1 H), 7.05 - 7.38 (m, 10 H), 7.75 (d, J = 7.3 Hz, 1 H), 7.81 (d, J = 6.9 Hz, 1 H), 7.86 (d, J = 8.0 Hz, 1 H), 8.10 (m, 2 H), 8.40 (d, J = 7.2 Hz, 1 H), 9.26 (s, 1 H), 11.50 - 12.50 (bs, 3 H); MS m/z 915 (M^+ + H)

Second fraction: RT: 12.2 min, 42 mg (20%), colourless powder after lyophilization;

^{1}H-NMR (DMSO-d_6) δ 0.76 - 0.94 (m, 2 H), 1.05 - 1.30 (m, 4 H), 1.32 - 1.50 (m, 2 H), 1.52 - 1.78 (m, 9 H), 1.83 (s, 3 H), 1.95 - 2.15 (m, 6 H), 2.25 - 2.45 (m, 2 H), 3.98 - 4.12 (m, 2 H),), 4.15 - 4.23 (m, 2 H), 4.35 - 4.51 (m, 2 H), 5.15 - 5.19 (m, 1 H), 6.06 (dt, J = 4.5, 56.1 Hz, 1 H), 7.07 - 7.38 (m, 10 H), 7.58 (d, J = 7.5 Hz, 1 H), 7.60 - 8.12 (m, 4 H), 8.43 (bs, 1 H), 9.32 (s, 1 H), 11.90 (bs, 3 H); MS m/z 915 (M^+ + H).

EXAMPLE 5: Synthesis of compound 1d

i) *(R,S)*-4-(tert.-Butyloxycarbonylamino)-6,6-difluoro- 3-oxo-2-triphenylphosphoranylidene-hexanenitrile

Using the method described by Wassermann et al in Journal of Organic Chemistry (1994), 4366, (±)-N-(tert-Butyloxycarbonyl)-2-amino-4,4-difluorobutyric (1.0 g, 4.18 mmol, prepared as described in example 4 (iv), EDC (841 mg, 4.39 mmol) and N,N-dimethylaminopyridine (51 mg, 0.42 mmol) were dissolved in dichloromethane (25 mL) and cooled to 0 °C. A solution of triphenylphosphoranyliden nitrile (2.52 g, 8.36 mmol) in dichloromethane (16 mL) was added dropwise. After the addition the reaction was allowed to reach room temperature and stirred for 6 h. Then ethyl acetate (150 mL) was added and the solution washed successively with 0.5 M aqueous $KHSO_4$, water and brine (2x 100 mL). Drying (Na_2SO_4) and evaporation gave an orange solid, which was purified by flash chromatography on silica gel (PE/ethyl acetate 2 : 1 to 1.5 : 1). 1.21 g (54%) of a colorless solid were obtained; m.p. 194-195 °C (n-heptane/dichloromethane). ^{1}H-NMR ($CDCl_3$) δ 1.41 (s, 9 H), 2.12 - 2.28 (m, 1 H), 2.38 - 2.70 (m, 1 H), 5.00 (m, 1 H), 5.41 (bs, 1 H), 5.92 (tt, J = 4.5, 56.2 Hz, 1 H), 7.41 - 7.78 (m, 15 H); ^{19}F-NMR ($CDCl_3$) δ -113.8 (d, J = 287 Hz), -114.1 (d, J = 287 Hz); MS *m/z* 523 (M^+ + H).

ii) (±)-Methyl-3-(tert.-butyloxycarbonylamino)-5,5-difluoro-2-hydroxy-pentanoate

The foregoing compound (700 mg, 1.34 mmol) was dissolved in dichloromethane / methanol (13 ml, 7 : 3, v/v) and cooled to -78 °C. Ozone was bubbled through the solution until the blue color remained. The solution was then purged with nitrogen and stirred at room temperature for 4 h. Evaporation gave a light yellow oil, which was dissolved in methanol (10 mL) and cooled to 0 °C. Solid sodium tetrahydroborate (146 mg, 3.86 mmol) was added

portionwise. After 30 min ethyl acetate (50 mL) was added followed by 0.5 N HCl (5 mL). After stirring the mixture for 5 min, the organic phase was separated, washed with 1 N HCl, water and brine. Drying (Na_2SO_4) and evaporation gave a yellow oil, which was purified by flash chromatography on silica gel (PE/ethyl acetate 2.5 : 1).182 mg (50%) of a colorless waxy solid were obtained. 2 diastereomers (1.5 : 1). For analytical purposes some fractions containing the single diastereomers were collected.

1. Fraction (major diastereomer), m.p. 103 - 104 °C (n-pentane/CH_2Cl_2). ^{1}H-NMR ($CDCl_3$) δ 1.41 (s, 9 H), 2.10 - 2.23 (m, 2 H), 3.32 (d, *J* = 4.4 Hz, 1 H), 3.81 (s, 3 H), 4.20 (dd, *J* = 1.6, 4.4 Hz, 1 H), 4.33 (m, 1 H), 4.87 (d, *J* = 9.8 Hz, 1 H), 5.96 (tt, *J* = 4.5, 56.1 Hz, 1 H); ^{13}C-NMR ($CDCl_3$) δ 28.2, 37.1 (t, *J* = 22.5 Hz), 48.3, 53.0, 72.3, 80.2, 115.7 (t, *J* = 238 Hz), 155.1, 173.2; ^{19}F-NMR ($CDCl_3$) δ -114.4 (d, *J* = 287 Hz), -115.1 (d, *J* = 287 Hz); MS *m/z* 283 (M^+ + H).

2. Fraction (minor diastereomer), m.p. 118 - 119 °C (n-pentane/CH_2Cl_2). ^{1}H-NMR ($CDCl_3$) δ 1.45 (s, 9 H), 1.78 - 1.85 (m, 1 H), 2.02 - 2.11 (m, 1 H), 3.17 (bs, 1 H), 3.84 (s, 3 H), 4.26 (bm, 1 H), 4.35 (bs, 1 H), 4.97 (d, *J* = 8.2 Hz, 1 H), 5.94 (ddt, *J* = 3.3, 5.9, 56.2 Hz, 1 H); ^{13}C-NMR ($CDCl_3$) δ 28.3, 34.6 (t, *J* = 21.2 Hz), 48.6, 53.1, 72.8, 80.3, 115.8 (t, *J* = 238 Hz), 155.3, 172.7; ^{19}F-NMR ($CDCl_3$) δ -114.0 (d, *J* = 286 Hz), -114.8 (d, *J* = 286 Hz); MS *m/z* 283 (M^+ + H).

iii) <u>(*R,S*)-Methyl-3-amino-5,5-difluoro-2-hydroxy-pentanoate hydrochloride</u>

1.54 g (5.46 mmol) of the diastereomeric mixture of the foregoing compound were treated with a solution of gaseous hydrochloric acid in ethyl acetate (3 M, 36 mL) at 0 °C. After 30 min the cooling bath was removed and the solution stirred at room temperature for 1.5 h. Evaporation gave the title compound as a yellow solid,

1.19 g (100%); 2 diastereomers: 1.3 : 1*). ^{1}H-NMR (DMSO-d_6) δ 1.95 - 2.36 (m, 1 H), 3.47 - 3.61 (m, 1 H), 3.68, 3.69* (s, 3 H), 4.36 (d, J = 3.6 Hz, 1 H), 4.58* (d, J = 2.5 Hz, 1 H), 6.32* (ddt, J = 3.6, 5.7, 56 Hz, 1 H), 6.36 (dt, J = 4.7, 55.8 Hz, 1 H), 6.45*, 6.69 (bs, 1 H), 8.41, 8.60* (bs, 3 H); ^{13}C-NMR (DMSO-d_6) δ 32.4*, 33.8 (t, J = 22.3*, 22.2 Hz), 47.6*, 47.7, 52.15*, 52.2, 69.0, 69.7*, 115.4 (t, J = 236 Hz), 170.8; ^{19}F-NMR (DMSO-d_6) δ -114.3*, -114.6 (d, J = 284 Hz), -115.2*, -115.6 (d, J = 284 Hz); MS m/z 183 (M^+ + H, free amine).

iv) (1d)

150 mg pentapeptide (0.153 mmol) were dissolved in dimethylformamide (2 mL). HATU (64 mg, 0.17 mmol) and 2,6-lutidine (49 mg, 0.46 mmol) were added and the solution cooled to 0 °C. (±)-Methyl-3-amino-5,5-difluoro-2-hydroxy-pentanoate hydrochloride (40 mg, 0.18 mmol; prepared as above) was added as a solid. The cooling bath was removed after 30 min and the resulting solution stirred overnight. The reaction was taken into a mixture of ethyl acetate and dichloromethane (150 mL, 3 : 1) and washed successively with 1 M aqueous $KHSO_4$, (3x 80 mL), water (2x 100 mL), saturated aqueous $NaHCO_3$ and brine (2x 100 mL). Drying (Na_2SO_4) and evaporation gave a solid which was oxidized with Dess-Martin periodinane (195 mg, 0.46 mmol) in dichloromethane (3 mL) and tert.-butanol (34 mg, 0.46 mmol). After stirring at room temperature for 24 h, ethyl acetate (50 mL) was added. The organic phase was washed 3x with a mixture of aqueous saturated sodium hydrogen carbonate and aqueous saturated sodium thiosulfate (1:1, v/v), then with brine. Drying (Na_2SO_4) and evaporation gave a solid which was deprotected with a solution of trifluoroacetic acid, dichloromethane and water (50/45/5, v/v/v; 20 mL). After 30 min at room temperature the solvents were evaporated in vacuo and the remaining solid (158 mg) dissolved in methanol (4 mL). Aqueous sodium hydroxide (1 mL, 1 N) was added and the

solution left at room temperature for 15 min. Then aqueous hydrochloric acid (1 mL, 1 N) was added and the solution diluted with water / acetonitrile (70/30, v/v) and lyophilized. The product was isolated by preparative HPLC (Nova-Pak Prep). Flow 35 mL/min; Gradient: linear, 75% A, 5 min isocratic, in 10 min to 50% A; 20 mg of crude per injection.
First fraction: RT: 12.8 min, 50 mg (34%) of a colorless powder after lyophilization; 1 diastereomer, 99% pure by analytical HPLC (gradient 1, 6.9 min; gradient 2, 6.45 min). In the ^{1}H-NMR 15 - 20% of the ketoacid was hydrated. Addition of water gave a ratio of ketoacid to hydrate of 1 : 1. Only data for the ketoacid are reported. ^{1}H-NMR (DMSO-d_6) δ 0.77 - 0.92 (m, 2 H), 1.05 - 1.43 (m, 6 H), 1.52 - 1.78 (m, 9 H), 1.82 (s, 3 H), 1.97 - 2.17 (m, 5 H), 2.30 - 2.50 (m, 3 H), 4.02 - 4.19 (m, 3 H), 4.37 (d, J = 10.3 Hz, 1 H), 4.49 (m, 1 H), 4.92 (m, 1 H), 5.21 (app. t, J = 9.3 Hz, 1 H), 6.08 (ddt, J = 3.3, 5.5, 56.0 Hz, 1 H), 7.03 - 7.38 (m, 10 H), 7.72 (d, J = 7.3 Hz, 1 H), 7.78 (d, J = 7.7 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 1 H), 7.90 (d, J = 7.9 Hz, 1 H), 8.12 (d, J = 7.6 Hz, 1 H), 8.49 (d, J = 7.0 Hz, 1 H); MS m/z 959.9 (M^+ + H).

Second fraction: RT: 13.9 min, 51 mg (34%), colorless powder after lyophilization; 1 diastereomer, 97% pure by analytical HPLC (gradient 1, 7.3 min). ^{1}H-NMR (DMSO-d_6) δ 0.73 - 0.98 (m, 2 H), 1.05 - 1.50 (m, 6 H), 1.52 - 1.84 (m, 9 H), 1.84 (s, 3 H), 1.97 - 2.22 (m, 5 H), 2.30 - 2.50 (m, 3 H), 4.03 - 4.26 (m, 3 H), 4.39 (d, J = 10.2 Hz, 1 H), 4.49 (m, 1 H), 4.74 (m, 1 H), 5.21 (app. t, J = 9.2 Hz, 1 H), 6.06 (ddt, J = 3.6, 5.4, 56.4 Hz, 1 H), 7.03 - 7.38 (m, 10 H), 7.69 (d, J = 7.5 Hz, 1 H), 7.79 (d, J = 7.8 Hz, 1 H), 7.82 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 8.1 Hz, 1 H), 8.13 (d, J = 7.8 Hz, 1 H), 8.59 (d, J = 6.9 Hz, 1 H); MS m/z 959.6 (M^+ + H).

EXAMPLE 6: Synthesis of compound (2a)

The protected tripeptide shown below (Ac-Diphenylala-tert-butyl-Glu-β-Cyclohexylala) was employed in this example.



200 mg tripeptide (0.32 mmol) and HATU (129 mg, 0.34 mmol) were dissolved in dimethylformamide (2 mL) and the solution cooled to 0 °C. (±)-Methyl-3-amino-5,5-difluoro-2-hydroxy-pentanoate hydrochloride (77 mg, 0.35 mmol, prepared as described in example 5 (iii)) in DMF (1 mL) and 2,6-lutidine (103 mg, 0.96 mmol) were added and the solution allowed to reach room temperature and stirred overnight. The reaction was taken into ethyl acetate (60 mL) and washed successively with 1 M aqueous $KHSO_4$, (2x 30 mL), water, saturated aqueous $NaHCO_3$ and brine (2x 30 mL each). Drying (Na_2SO_4) and evaporation gave a 235 mg of a solid. 231 mg of this material were oxidized with Dess-Martin periodinane (374 mg, 0.88 mmol) in dichloromethane (2 mL) and tert.-butanol (65 mg, 0.88 mmol). After stirring at room temperature for 3 h, analytical HPLC indicated complete conversion of the starting material. Ethyl acetate (100 mL) was added. The organic phase was washed 2x with a mixture of aqueous saturated sodium hydrogen carbonate and aqueous saturated sodium thiosulfate (1:1, v/v, 50 mL), then with brine. Drying (Na_2SO_4) and evaporation gave 220 mg of a colorless solid which was deprotected with a solution of trifluoroacetic acid, dichloromethane and water (60/35/5, v/v/v; 20 mL). After 30 min at room temperature the solvents were evaporated in vacuo to give a light yellow solid (221 mg). 150 mg of this material were dissolved in methanol (4 mL) and aqueous sodium hydroxide (1 mL, 1 N) was added. The solution was left at room temperature for 20

min. Then aqueous hydrochloric acid (1 mL, 1 N) was added and the solution diluted with water / acetonitrile (70/30, v/v, 15 mL) and lyophilized. The product was isolated by preparative HPLC (Nova-Pak Prep). Flow 30 mL/min; Gradient : linear, 70% A, 5 min isocratic, in 13 min to 44% A; 10 - 12 mg of crude per injection. First fraction: RT: 13.6 min, 21 mg (14%) of a colorless powder after lyophilization; 1 diastereomer, 99% pure by analytical HPLC (gradient 1, 7.34 min, gradient 2, 7.72 min). In the ^{1}H-NMR 10 - 15% of the ketone was hydrated. Addition of water increased the ratio of ketoacid to hydrate to 1 : 1. Only data for the ketoacid are reported. ^{1}H-NMR (DMSO-d_6) δ 0.73 - 0.91 (m, 2 H), 1.02 - 1.24 (m, 4 H), 1.24 - 1.43 (m, 2 H), 1.52 - 1.70 (m, 6 H), 1.65 (s, 3 H), 1.71 - 1.82 (m, 1 H), 1.96 - 2.08 (m, 2 H), 2.08 - 2.23 (m, 1 H), 2.28 - 2.40 (m, 1 H), 4.06 (m, 1 H), 4.15 (m, 1 H), 4.32 (d, J = 11.1 Hz, 1 H), 4.92 (m, 1 H), 5.22 (dd, J = 8.7, 11.1 Hz, 1 H), 6.08 (ddt, J = 3.6, 5.7, 55.9 Hz, 1 H), 7.04 - 7.32 (m, 10 H), 7.72 (d, J = 7.4 Hz, 1 H), 7.87 (d, J = 8.1 Hz, 1 H), 8.15 (d, J = 8.7 Hz, 1 H), 8.54 (d, J = 7.1 Hz, 1 H); MS m/z 715 (M^+ + H).

Second fraction: RT: 14.8 min, 23 mg (15%), colorless powder after lyophilization; ^{1}H-NMR (DMSO-d_6) δ 0.74 - 0.93 (m, 2 H), 1.04 - 1.24 (m, 4 H), 1.24 - 1.43 (m, 2 H), 1.52 - 1.70 (m, 6 H), 1.65 (s, 3 H), 1.71 - 1.82 (m, 1 H), 1.96 - 2.08 (m, 2 H), 2.08 - 2.21 (m, 1 H), 2.28 - 2.39 (m, 1 H), 4.07 (m, 1 H), 4.16 (m, 1 H), 4.32 (d, J = 11.1 Hz, 1 H), 4.73 (m, 1 H), 5.21 (dd, J = 8.7, 11.1 Hz, 1 H), 6.06 (ddt, J = 3.6, 5.5, 56.4 Hz, 1 H), 7.04 - 7.32 (m, 10 H), 7.69 (d, J = 7.5 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 8.15 (d, J = 8.6 Hz, 1 H), 8.70 (d, J = 7.0 Hz, 1 H); MS m/z 715 (M^+ + H).

EXAMPLE 7: Synthesis of compound 3c

i) (*R,S*)-4-Amino-6,6-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile

A solution of (±)-N-(Benzyloxycarbonyl)-2-amino-4,4-difluorobutyric acid (4.22 g, prepared as described in example 3 (iv), but using racemic difluoroaminobutyric acid), EDC (3.25 g, 16.94 mmol) and HOBt (2.49 g, 18.48 mmol) in dichloromethane (150 mL) was cooled to 0 °C. A solution of triphenylphosphoranyliden nitrile (10.2 g, 33.97 mmol) was added dropwise over 2 h. After addition, the cooling bath was removed and the mixture stirred at room temperature for 24 h. The reaction mixture was washed successively with 1 N aqueous HCl, water, saturated aqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave a solid, which was recrystallized from petrol ether / ethyl acetate to give 6.58 g of (±)-4-(N-(Benzyloxycarbonyl-amino)-6,6-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile as a colorless powder. The mother liquor was evaporated and the solid separated by flash column chromatography on silica gel (toluene / ethyl acetate 2 : 1) to yield another 441 mg (combined yield 82%). ^{1}H-NMR (DMSO-d_6) δ 2.01 - 2.23 (m, 1 H), 2.26 - 2.45 (m, 1 H), 4.73 (m, 1 H), 5.03 (d, *J* = 12.6 Hz, 1 H), 5.09 (d, *J* = 12.6 Hz, 1 H), 6.08 (ddt, *J* = 3.6, 5.7, 56.6 Hz, 1 H), 7.25 - 7.44 (m, 5 H), 7.48 - 7.70 (m, 13 H), 7.72 - 7.80 (m, 3 H); ^{19}F-NMR (DMSO-d_6) δ -114.6 (d, *J* = 282 Hz), -115.7 (d, *J* = 282 Hz); MS *m/z* 557 (M^+ + H).

3.00 g (5.34 mmol) of the foregoing compound and palladium on carbon (10% Pd, 6.0 g) were placed in a 500 mL flask. Methanol (150 mL) was added slowly under nitrogen, followed by ammonium acetate (4.0 g). The reaction was stirred at room temperaturefor 30 min, when thin layer chromatography (5% triethylamine in ethyl acetate) indicated complete conversion of starting material. The palladium catalyst was removed by filtration and washed extensively with ethyl acetate (500

mL). The filtrate was washed with aqueous saturated sodium hydrogencarbonate (2 x 200 mL) and brine. Drying (Na_2SO_4) and evaporation gave 1.90 g (84%) of the title compound as a colorless solid. %). ^{1}H-NMR (DMSO-d_6) δ 1.73 - 1.88 (m, 3 H), 2.09 - 2.23 (m, 1 H), 3.94 (dd, *J* = 4.1, 9.8 Hz, 1 H), 6.13 (ddt, *J* = 2.8, 6.8, 57.1 Hz, 1 H), 7.55 - 7.69 (m, 12 H), 7.70 - 7.78 (m, 3 H); ^{19}F-NMR (DMSO-d_6) d -114.8 (d, *J* = 280 Hz), -115.8 (d, *J* = 280 Hz); MS *m/z* 423 (M^+ + H).

ii) (3c)

The protected dipeptide shown below (Cbz-Ile-LeuOH) was used in this example.



The dipeptide (184 mg, 0.49 mmol) was dissolved in dichloromethane (4 mL) and EDC (102 mg, 0.54 mmol) and HOBt (72 mg, 0.54 mg) were added. The resulting solution was cooled to 0 °C and (±)-4-Amino-6,6-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile (226 mg, 0.54 mmol) was added in one portion. The ice bath was removed and the mixture stirred at room temperature for 90 min. The reaction mixture was diluted with ethyl acetate and washed successively with 1 N aqueous HCl, water, saturated aqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave a solid which was purified by flash chromatography (PE / ethyl acetate 1 : 2) to give 319 mg (83%) of Cbz-Ile-Leu-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile as a colorless powder (mixure of diastereomers, 2 :1*). ^{1}H-NMR (DMSO-d_6) δ 0.72 - 0.88 (m, 12 H), 1.04 - 1.15 (m, 1 H), 1.34 - 1.49 (m, 3 H), 1.52 - 1.63 (m, 1 H), 1.63 - 1.76 (m, 1 H), 2.00 - 2.22 (m, 1 H), 2.26 - 2.43 (m, 1 H), 3.88 (app. t, *J* = 8.1 Hz, 1 H), 4.30 (dd, *J* = 8.2, 14.6 Hz, 1

H), 4.36* (dd, J = 8.2, 15.6 Hz, 1 H), 4.92 - 5.10 (m, 3 H), 5.97, 5.99* (m, 1 H), 7.23 - 7.40 (m, 5 H), 7.51 - 7.68 (m, 12 H), 7.69 - 7.77 (m, 3 H), 7.89* (d, J = 8.5 Hz, 1 H), 7.94 (d, J = 8.0 Hz, 1 H), 8.07* (d, J = 7.9 Hz, 1 H), 8.18 (d, J = 7.9 Hz, 1 H). MS m/z 783 (M^+ + H).

The foregoing compound (210 mg, 0.27 mmol) was dissolved in dichloromethane / methanol (6 ml, 7 : 3, v/v) and cooled to -78 °C. Ozone was bubbled through the solution until the blue color remained. The solution was then purged with nitrogen and stirred at room temperature for 2 h. Evaporation gave a light yellow oil, which purified by flash chromatography (PE / ethylacetate 1 : 1) to yield 103 mg (68%) of a colorless solid, which was dissolved in methanol (3 mL). Aqueous sodium hydroxide (1 N, 1 mL) was added and the solution stirred at room temperature for 30 min. After addition of hydrochloric acid (1 N, 1 mL), the mixture was diluted with water / acetonitrile (80 : 20, v/v). The product was isolated by preparative RP-HPLC (Waters Symmetry). Flow 17 mL/min; Gradient : linear, 70% A, 3 min isocratic, in 15 min to 40%.
First fraction: RT: 13.1 min, 8 mg (8%) of a colorless powder after lyophilization; 1 diastereomer. ^{1}H-NMR (DMSO-d_6) δ 0.75 - 0.91 (m, 12 H), 1.02 - 1.24 (m, 1 H), 1.34 - 1.47 (m, 3 H), 1.55 - 1.77 (m, 2 H), 2.02 - 2.20 (m, 1 H), 2.29 - 2.40 (m, 1 H), 3.89 (app. t, J = 8.2 Hz, 1 H), 4.28 (dd, J = 7.3, 15.4 Hz, 1 H), 4.93 (m, 1 H), 5.02 (d, J = 5.7 Hz, 2 H), 6.04 (tt, J = 3.2, 57.0 Hz, 1 H), 7.32 - 7.40 (m, 6 H), 7.96 (d, J = 7.6 Hz, 1 H), 8.44 (bs, 1 H). MS m/z 528 (M^+ + H).
The second fraction contained a 1 : 1 mixture of the two diastereomers (34 mg, 34%).

EXAMPLE 8: Synthesis of 5j

i) Leucine-6,6-difluoro-3-oxo-2-triphenyl-phosphoranylidene-pentanenitrile

Cbz-L-Leucine (760 mg, 2.80 mmol), EDC (598 mg, 3.12 mmol) and HOBt (421 mg, 3.12 mmol) were dissolved in dichloromethane (15 mL) and cooled to 0 °C. A solution of (±)-4-Amino-6,6-difluoro-3-oxo-2-triphenyl-phosphoranylidene-hexanenitrile (1.10 g, 2.60 mmol) (prepared as described in example 7, i)) in dichloromethane (13 mL) was added dropwise. The resulting mixture was stirred overnight at room temperature, then ethyl acetate (200 mL) was added and the mixture washed successively with 1 N aqueous HCl, water, saturated aqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave a solid, which was purified by flash chromatography (PE/ethylacetate 1 : 2) to afford 1.50 g of a colorless solid (2 diastereomers, 1.5 : 1*). ^{1}H-NMR (DMSO-d_6) δ 0.77 - 0.89 (m, 6 H), 1.38 - 1.49 (m, 2 H), 1.55 - 1.67 (m, 1 H), 2.03 - 2.21 (m, 1 H), 2.27 - 2.42 (m, 1 H), 4.06 (m, 1 H), 4.96 (m, 1 H), 5.01 (d, J = 11.1 Hz, 2 H), 5.95, 6.01* (m, 1 H), 7.22 - 7.38 (m, 5 H), 7.50 - 7.68 (m, 12 H), 7.70 - 7.79 (m, 3 H), 7.37 (d, J = 8.8 Hz, 1 H), 7.41* (d, J = 9.0 Hz, 1 H), 8.11 (d, J = 7.9 Hz, 1 H), 8.15* (d, J = 7.8 Hz, 1 H). MS m/z 670 (M^+ + H).

To the foregoing compound (1.35 g, 2.02 mmol) and palladium on carbon (10% Pd, 2.8 g) was slowly added methanol (70 mL) under nitrogen, followed by ammonium acetate (2.0 g). The reaction was stirred at room temperaturefor 20 min, when thin layer chromatography (5% triethylamine in ethyl acetate) indicated complete conversion of starting material. The palladium catalyst was removed by filtration and washed extensively with ethyl acetate (300 mL). The filtrate was washed with aqueous saturated sodium hydrogencarbonate / brine (200 mL, 1/1, v/v) and then with brine. Drying (Na_2SO_4) and evaporation gave 976 mg (84%) of the title compound as a colorless solid (2 diastereomers, 1 : 1*). ^{1}H-NMR (DMSO-

d_6) δ 0.83 (d, J = 6.5 Hz, 3 H), 0.84* (d, J = 6.5 Hz, 3 H), 0.86 (d, J = 6.5 Hz, 3 H), 0.88* (d, J = 6.5 Hz, 3 H), 1.24 - 1.32 (m, 1 H), 1.42 - 1.49 (m, 1 H), 1.66 - 1.74 (m, 1 H), 2.03 - 2.24 (m, 1 H), 2.28 - 2.44 (m, 1 H), 3.27 (m, 3 H),, 4.98 (m, 1 H), 5.01 (d, J = 11.1 Hz, 2 H), 6.00, 6.04* (m, 1 H), 7.55 - 7.68 (m, 12 H), 7.70 - 7.80 (m, 3 H), 7.85 (d, J = 8.2 Hz, 1 H), 7.52* (d, J = 8.2 Hz, 1 H),, 8.26 (d, J = 7.9 Hz, 1 H), 8.36* (d, J = 7.9 Hz, 1 H). ^{19}F-NMR (DMSO-d_6) δ -113.8, -114.0* (d, J = 281 Hz), -114.7, -114.9 (d, J = 281 Hz); MS m/z 536 (M^+ + H).

ii) (5j)

To a solution of BocGlu(OBn)OH (265 mg, 0.78 mmol) in dichloromethane (8 mL) was added EDC (158 mg, 0.82 mmol) and HOBt•H_2O (137 mg, 0.9 mmol) at 0° C. After 10 min the foregoing compound (400 mg, 0.747 mmol) was added as a solid. After stirring overnight, the reaction was worked up as described in example 7, ii). 550 mg (0.64 mmol) of the crude product were dissolved in methanol (30 mL). Palladium on charcoal (1 g, 10%Pd) was added carefully, followed by ammonium formate (1.5 g). After 20 min workup was conducted as described in example 7, ii). An offwhite solid (419 mg, 85%) was obtained. 410 mg of this material were ozonized in dichloromethane (20 mL) at -78° C. After the solution turned blue, ozonization was continued until TLC (PE / ethyl acetate 1:1) indicated complete consumption of the starting material. The ozone was removed by bubbling nitrogen through the reaction and THF / water (4 : 1, v/v, 10 mL) was added. The cooling bath was removed and the mixture stirred at room temperature for 3 h. Evaporation gave a light yellow oil, which purified by medium pressure chromatography (acetonitrile water 3 : 7) using a RP C18 Lobar column (Fa. Merck KGA, Darmstadt) to yield 224 mg of a colorless powder after lyophilization. The product was isolated by preparative

RP-HPLC (Waters Symmetry). Flow 17 mL/min; Gradient : linear, 80% A, 3 min isocratic, in 12 min to 50%. First fraction: RT: 10.2 min, 40 mg (15%) of a colorless powder after lyophilization; 1 diastereomer. ^{1}H-NMR (DMSO-d_6) δ 0.80 - 0.92 (m, 6 H), 1.37 (s, 9 H), 1.50 - 1.70 (m, 2 H), 1.55 - 1.72 (m, 1 H), 1.77 - 1.89 (m, 1 H), 2.10 - 2.24 (m, 1 H), 2.23 (m, 2 H), 2.30 - 2.42 (m, 1 H), 3.90 (m, 1 H), 4.27 (m, 1 H), 4.91 (m, 1 H), 6.04 (tt, *J* = 3.6, 56.8 Hz, 1 H), 6.93 (bs, 1 H), 7.84 (d, *J* = 7.5 Hz, 1 H), 8.60 (bs, 1 H). MS *m/z* 510 (M^+ + H). Second fraction: RT: 11.3 min, 50 mg (18%) of a colorless powder after lyophilization; 1 diastereomer. ^{1}H-NMR (DMSO-d_6) δ 0.78 - 0.90 (m, 6 H), 1.37 (s, 9 H), 1.50 - 1.70 (m, 2 H), 1.55 - 1.72 (m, 1 H), 1.77 - 1.89 (m, 1 H), 2.10 - 2.24 (m, 1 H), 2.23 (m, 2 H), 2.30 - 2.42 (m, 1 H), 3.90 (m, 1 H), 4.27 (m, 1 H), 4.70 (m, 1 H), 6.03 (tt, *J* = 3.7, 57.2 Hz, 1 H), 6.94 (ds, *J* = 7.8 Hz, 1 H), 7.84 (d, *J* = 7.6 Hz, 1 H), 8.70 (bs, 1 H). MS *m/z* 510 (M^+ + H).

EXAMPLE 9: Synthesis of compound 9x

i) Synthesis of compound 15 (see scheme 7)
Boc-Leu-OH (1.16 g, 5 mmol) was dissolved in dichloromethane (50 mL) and EDC (1.05 g, 5.5 mmol) and HOBt (743 mg, 5.5 mmol) were added. The resulting solution was cooled to 0 °C and (±)-4-Amino-6,6-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile (2.32 g, 5.5 mmol) was added in one portion. The ice bath was removed and the mixture stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane (100 mL) and washed successively with 1 N aqueous HCl, water, saturated aqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave 2.7 g (85 %) of Boc-Leu-6,6-difluoro-3-oxo-2-triphenylphosphoranylidene-hexanenitrile as a yellowish foam. The foregoing compound (2.7 g, 4.2 mmol) was dissolved in dichloromethane /

methanol (40 ml, 7 : 3, v/v) and cooled to -78 °C. Ozone was bubbled through the solution until the blue color remained. The solution was then purged with nitrogen and 12 mL of MeOH were added, the resulting solution was stirred at -78°C for 30 min. and at room temperature for 2 h. Evaporation gave a light yellow oil, which was dissolved in MeOH (6 mL) and the resulting solution was cooled to 0°C. After addition portionwise of $NaBH_4$ (159 mg, 4.2 mmol) the resulting reaction mixture was stirred at 0°C for 2 hours, poured into saturated aqueous $NaHCO_3$ and extracted with EtOAc. The combined organic layers were washed with brine and dried (Na_2SO_4). Evaporation gave a solid which was purified by flash chromatography (PE / ethyl acetate 3 : 2) to give 832 mg (50%) of the Boc protected dipeptide hydroxyester.
The above compound (832 mg, 2.1 mmol) was dissolved in EtOAc (8 mL) and cooled to 0°C. To the resulting solution 4 N HCl in dioxane (2.6 mL, 10.5 mmol) was added. The reaction was stirred at room temperature for 2 hours. The solvent was evaporated giving 670 mg (96%) of 15 as a pale yellow foam (mixture of four diastereomers). ^{1}H-NMR (DMSO-d_6) δ 8.84 (d, J = 8.0 Hz, 1 H), 8.73 (d, J = 8.9 Hz, 1 H), 8.84 (br t, 2 H), 8.33-8.20 (m, 8 H), 6.25-5.83 (m, 4 H), 4.36-4.18 (m, 4 H), 3.78-3.60 (m, 4 H), 3.66 (s, 3 H), 3.62 (s, 6 H), 3.56 (s, 3 H), 2.20-1.94 (m, 8 H), 1.65-1.42 (m, 9 H), 0.89-0.86 (m, 24 H); MS m/z 297 (M^+ + H).

ii) Synthesis of compound 16 (see scheme 7)

To a solution of (±) indoline-2-carboxylic acid (2.33 g, 20 mmol) and Et_3N (5.6 mL, 40 mmol) in MeOH (40 mL) cooled to 0°C was added portionwise Boc_2O (5.24 g, 24 mmol). The ice bath was removed and the mixture stirred at room temperature for 18 hours. After evaporation of the solvent the resulting oil was dissolved in EtOAc and washed successively with 1 N acqueous HCl and brine. Drying (Na_2SO_4) and evaporation gave 4.48 g (85%) of a

white solid. The N-Boc protected indoline-2-carboxylic acid (4.48 g, 17 mmol) was dissolved in DMF (50 mL) and cesium carbonate (5.54 g, 17 mmol) and benzyl bromide (1.65 mL, 16.2 mmol) were added. The resulting solution was stirred at room temperature for 24 hours. The reaction mixture was diluted with EtOAc and washed with 1 N acqueous HCl, saturated acqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave an oil, which was purified by flash chomatography column on silica gel (petroleum ether / ethyl acetate 12 : 1) to give 5.42 g (95%) of the protected indoline.
To a solution KHMDS (0.5N in toluene, 8 ml, 4 mmol) in THF (6 ml) cooled to -78°C was added dropwise a solution of the N-Boc protected benzyl indoline-2-carboxylate (706 mg, 2 mmol) in THF (4 ml). The resulting solution was stirred at -40°C for 1 hour. After cooling down to -78°C, a solution of tert-butyl 3-(bromomethythiophene-2-carboxylate (1.66 g, 6 mmol) in THF (4 ml) was added dropwise. The reaction mixture was allowed to warm-up slowly (5 hours) to room temperature and diluted with EtOAc (100 ml). The organic layer was washed with 1 N acqueous HCl, saturated acqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave an oil, which was purified by flash chromatography column on silica gel (petroleum ether / ethyl acetate 8 : 1) to give 935 mg (85%) of the fully protected alkylated indoline. ^{1}H-NMR (DMSO-d_6) δ 7.50 (d, J = 5.2 Hz, 1 H), 7.34 (s, 5 H), 7.03 (t, J = 8.0 Hz, 1 H), 6.91 (d, J = 7.3 Hz, 1 H), 6.78 (t, J = 7.4 Hz, 1 H), 6.72 (d, J = 5.1 Hz, 1 H), 5.25 (d, J = 12.7 Hz, 1 H), 5.20 (d, J = 12.7 Hz, 1 H), 4.16 (d, J = 14.2 Hz, 1 H), 3.70 (d, J = 14.2 Hz, 1 H), 3.29 (s, 2 H), 1.51 (s, 9 H), 1.48 (s, 9 H); MS m/z 550 (M^+ + H).

To a solution of the foregoing compound (935 mg, 1.7 mmol) in MeOH (50 ml) was added Pd/C 30% (160 mg). The reaction mixture was stirred at room temperature under hydrogen (atmospheric pressure) for 18 hours. After dilution with EtOAc and filtration a colourless solution

was obtained. Evaporation of the solvent gave 781 mg (100%) of the alkylated indoline carboxylic acid (16) as an oil.

iii) (9x)

To a solution of the acid 16 (230 mg, 0.5 mmol), the dipeptide-hydroxyester 15 (200 mg, 0.6 mmol) and HATU (285 mg, 075 mmol) in dichloromethane (5 ml) cooled to 0°C, was added diisopropylethyl amine (0.22 ml, 1.25 mmol). After addition the cooling bath was removed and the mixture stirred at room temperature for three days. The reaction mixture was diluted with EtOAc (100 ml), washed with 1 N acqueous HCl, saturated acqueous $NaHCO_3$ and brine. Drying (Na_2SO_4) and evaporation gave an oil, which was purified by flash chromatography column on silica gel (petroleum ether / ethyl acetate 2 : 1) to give 197 mg (53%) of the coupling product as a mixture of 8 diastereomers. ^{1}H-NMR (DMSO-d_6) δ 7.60-6.56 (m, 7 H), 6.10-5.68 (m, 1 H), 4.43-3.94 (m, 3 H), 3.65-3.54 (m, 3 H), 3.44-3.10 (m, 2 H), 2.17-1.89 (m, 2 H), 1.67-1.40 (m, 18 H), 0.90-0.86 (m, 6 H); MS *m/z* 738 (M^+ + H).

To a solution of the foregoing compound (197 mg, 0.26mmol) in dichloromethane (4 ml) and ^{t}BuOH (4 drops) was added DMP (331 mg, 0.78 mmol) at room temperature. After stirring for 3 hours the reaction mixture was diluted with EtOAc (100 ml), washed with saturated acqueous $NaHCO_3$ and saturated acqueous $Na_2S_2O_3$ (1 : 1) and brine. Drying (Na_2SO_4) and evaporation gave 195 mg of the ketoester as an oil, which was dissolved in TFA/dichloromethane/water (65:30:5) (30 mL) and stirred at room temperature for 3 hours. After evaporation of the solvent an oil was obtained, which was dissolved in methanol (20 mL). Aqueous sodium hydroxide (1 N, 10 mL) was added and the solution stirred at room temperature for 12 min. After addition of hydrochloric acid (1 N, 1 mL), the mixture was diluted with water / acetonitrile (80 : 20, v/v). The product was isolated by preparative

RP-HPLC (Waters Symmetry). Flow 25 mL/min; Gradient : linear, 80% A, 2 min isocratic, in 43 min to 60% as the trifluoroacetate.
First fraction: RT: 8.5 min, 12 mg (7%) of a colourless powder after lyophilization; 1 diastereomer.
^{1}H-NMR (DMSO-d_6) δ 8.75 (d, J = 6.9 Hz, 1 H), 7.82 (d, J = 8.3 Hz, 1 H), 7.53 (d, J = 5.1 Hz, 1 H), 7.04 (d, J = 5.1 Hz, 1 H), 6.86 (br d, J = 5.9 Hz, 2 H), 8.75 (m, 2 H), 6.11 (br t, J = 56.0 Hz, 1 H), 4.95 (br d, J = 3.7 Hz, 1 H), 4.34 (br s, 1 H), 3.72 (d, J = 13.6 Hz, 1 H), 3.09 (s, 1 H), 2.44-2.13 (m, 3 H), 1.42 (br s, 2 H), 0.80 (br s, 6 H); ^{19}F-NMR (DMSO-d_6) δ -114.9 (d, J = 282 Hz), -114.1 (d, J = 282 Hz); MS m/z 566 (M^+ + H).

2. INHIBITION OF NS3 PROTEASE

The ability of the compounds to inhibit NS3 protease was evaluated using an NS3/4A complex comprising the NS3 protease domain and a modified form of the NS4A peptide, Pep 4AK [KKKGSVVIVGRIILSGR(NH_2)]. As substrate, a substrate peptide 4AB [DEMEECASHLPYK] based on the sequence of the NS4A/NS4B cleavage site of the HCV polyprotein, was used

Cleavage assays were performed in 57µl 50 mM Hepes pH7.5, 1 % CHAPS, 15 % glycerol, 10 mM DTT (buffer A), to which 3µl substrate peptide were added. As protease co-factor a peptide spanning the central hydrophobic core (residues 21-34) of the NS4A protein, Pep4AK [KKKGSVVIVGRIILSGR(NH_2)] was used. Buffer solutions containing 80 µM Pep4AK were preincubated for 10 minutes with 10-200 nM protease and reactions were started by addition of substrate. Six duplicate data points at different substrate concentrations were used to calculate kinetic parameters. Incubation times were chosen in order to obtain <7% substrate conversion and reactions were stopped by addition of 40 µl 1 % TFA. Cleavage of

peptide substrates was determined by HPLC using a Merck-Hitachi chromatograph equipped with an autosampler. 80 μl samples were injected on a Lichrospher C18 reversed phase cartridge column (4 x 74mm, 5µm, Merck) and fragments were separated using a 10-40 % acetonitrile gradient a 5%/min using a flow rate of 2.5ml/min. Peak detection was accomplished by monitoring both the absorbance at 220nm and tyrosine fluorescence (λ_{ex} = 260 nm, λ_{em} = 305nm). Cleavage products were quantitated by integration of chromatograms with respect to appropriate standards. Kinetic parameters were calculated from nonlinear least-squares fit of initial rates as a function of substrate concentration with the help of a Kaleidagraph software, assuming Michaelis-Menten kinetics.

K_i values of peptide inhibitors were calculated from substrate titration experiments performed in the presence of increasing amounts of inhibitor. Experimental data sets were simultaneously fitted to eq.1 using a multicurve fit macro with the help of a Sigmaplot software:

$$V = (V_{max}S)/(K_m(1+K_i/I)+S); \qquad \text{(eq.1)}$$

Alternatively, K_i values were derived from IC50 values, calculated using a four-parameter logistic function, according to eq.2:

$$IC50 - (1+S/K_m)K_i \qquad \text{(eq.2)}$$

Results for the compounds synthesized in Examples 1 to 9 above are tabulated below in Tables 1 to 4.

IC_{50} values were determined for a variety of hexapeptides, tetrapeptides, tripeptides, capped dipeptide keto acids and indoline keto acids, and these also are tabulated in Tables 1 to 4, which follow.

In the tables the column headed "isomeric ratio" indicates the diastereomeric ratio of the compounds as tested. In the compounds of Tables 1 and 2 there is only one stereocentre which gives rise to diastereomers, the P1 (difluorinated) amino acid. In this series, the L enantiomer is known to be preferred (see e.g. Table 4, entries 1b, 1c). Thus in Tables 1 and 2,"single" isomer indicates substantially pure diastereomer with L stereochemistry at P1. Where a ratio is given it is that of L to D enantiomer at P1.

The compounds of Tables 3 and 4 have multiple stereocentres. Some compounds were separated to yield a single diastereomer, which was usually more active than the other diastereomers, although those also may have useful activity. Compounds of the indoline series contain three stereocentres, which give rise to eight stereoisomers. No separation was attempted and the mixture was tested as that. All stereoisomers are believed to be present in roughly equal amounts in these mixtures.

Table 1

Entry	Structure	IC_{50}	isomer ratio
1a		3	single
1b		(L) 20 nM (D) 1 μM	single single
1c		(L) 0.5 nM (D) 43 nM	single single
1d		0.4 nM	single
1e		5 nM	2 : 1

Table 1

1f		800 nM	1 : 1
1g		100 nM	single
1h		3 μM	single
1i		150 nM	1 : 1
1j		600 nM	1 : 1

Table 1

1k		1 μM	3 : 1
1l		6 μM	single
1m		7 μM	single
1n		148 nM	1 : 1
1o		800 nM	2 : 1

Table 2

	STRUCTURE	IC50 (μM)	isomer ratio
2a		10	single
2b		11.4	1 : 1
2c		47	single
3a		16	4 : 1
3b		1.4	> 10 : 1
3c		1.4	single

Table 2

3d		9.3	2 : 1
3e		3	single
3f		3	single
3g		16	6 : 1
4a		6.5	1.8 : 1
4b		39	3 : 1

Table 2

4c		1.7	single
4d		0.44	single
4e		7.8	single
4f		1	single
5a		0.7	single
5b		1.2	single

Table 2

5c		1.5	9 : 1
5d		0.5	single
5f		8.9	single
5g		1.2	single
5h		1.5	single
5i		5.8	single

Table 2

5j		0.33	single
5k		2.1	single
5l		3.5	single
5m		1.6	single
5n		0.72	single
5o		0.3	> 10 :1

Table 2

5p		2.4	> 9 : 1
5q		1.6	> 9 : 1
5r		5.8	9 : 1
5s		3.8	4 : 1
5t		2.5	> 10 :1
5u		0.4	> 10 :1

Table 2

6a		26	> 9 : 1
6b		50	2 : 1

Table 3

			
	STRUCTURE	**IC50 (μM)**	**isomer ratio**
7a		**74**	**> 10 : 1**
7b		**56**	**single**
7c		**78**	**1.7 : 1**
7d		**6**	**> 10 :1**
7e		**4**	**4 : 1**
7f		**35**	**a)**

Table 3

7g		19	a)
7h		32	1.5 : 1
7i		20	single
7j		26	> 10 :1
7k		35	1 : 1 : 1 : 1
7l		1	single
7m		85	12 : 1
7n		7	> 10 : 1

Table 3

7o		22	1 : 1
7p		15	single
7q		2	8 : 1
8a		32	single, b)
8b		8	single
8c		7	> 10 : 1
8d		7	1.4 : 1
8e		13	single

Table 3

8f		42	single
8g		4	single
8h		6	single
8i		28	1 : 1 : 1 : 1
8j		100	1.5 : 1 : 1 : 1
8k		72	1 : 1 : 1: 1
8l		14	1 : 1
8m		60	c)

Table 3

8n		6	1 : 1
8o		56	1 : 1
8p		25	1 : 1
8q		25	1 : 1
8r		82	1 : 1
8s		18	single
a) undetermined mixture of regio- and stereoisomers			
b) cis-stereochemistry at cyclohexyl ring			
c) > 10 : 1 at P1; 1 : 1 mixture at lactone			

Table 4

			
	STRUCTURE	IC50 (μM)	isomer ratio
9a		50	single
9b		87	1 : 1 : 1
9c		92	1.5 : 1 : 1 : 1
9d		16	1 : 1 : 1
9e		69	2 : 2 : 1 : 1
9f		120	1 : 1

Table 4

9g		15	single
9h		81	a)
9i		20	single
9j		34	1 : 1
9k		69	1 : 1 : 1
9l		31	1 : 1 : 1
9m		57	> 10 :1
9n		81	1 : 1

Table 4

9o		45	1 : 1 : 1 : 1
9p		88	a)
9q		5	single
9r		100	1 : 1 : 1 : 1
9s		38	2 : 1 : 1 : 1
9t		9	2.7 : 2 : 1
9u		0.8	> 10 : 1
9v		24	3 : 1

Table 4

9w		3	1 : 1 : 1
9x		0.7	single
10a		25	single
10b		24	single
10c		100	1 : 1 : 1 : 1
10d		66	> 9 : 1
10e		18	single
10f		10	single

Table 4

10g		23	1 : 1
10h		16	1 : 1
10i		30	single
11		43	2 : 1.5 : 1 : 1
12		26	single, b)
13		70	single
14		10	single
a) mixture of eight possible diastereomers, ratio not determined			
b) stereochemistry on indoline ring is trans			

CLAIMS:

1. A fluorine containing oligopeptide of formula:

Y-B-A-X or Y-B-A'-X'

(FORMULA I) (FORMULA II)

wherein:

A is an amino acid residue of formula:



where m is 0 or 1.

A' is an amino acid residue of formula



where m is 0, or 1 and R_1 is a fluorine-substituted hydrocarbyl side chain containing from 1 to 15 carbon atoms;

B is a naturally or non-naturally occurring amino acid residue of formula:



wherein R_2 contains from 1 to 20 carbon atoms is a non-polar, or polar but uncharged sidechain or is a side chain containing an acidic functionality;

X is selected from the following:

$-CO_2R_8$; $-H$; $-OR_8$; $-CF_3$; $-CONR_9R_{10}$; $-CF_2CONR_9R_{10}$; $-NH.SO_2R_{25}$ or a heterocyclic group of formula:



wherein U is sulphur, oxygen or NR_{11}; R_8, R_9, R_{10}, R_{11} and R_{25} are, independently, hydrogen or a lower alkyl, lower alkenyl, aryl, or aralkyl group, and S and T are each independently either H or R_{12}, where R_{12} is a lower alkyl, lower alkenyl, aryl or aralkyl group, or can together form a ring;

X' is OH or $-NHSO_2R_{25}$, where R_{25} is as defined above;

and Y is selected from (i) and (ii) below:

(i) Z-F-E-D-C-}

wherein C is a natural or non-natural amino acid residue having a non-polar, polar but uncharged, or acidic side chain containing from 1 to 20 carbon atoms;

D may be absent, but where present is a natural or non-natural amino acid having a hydrophobic side chain containing 1 to 20 carbon atoms;

E may be absent, but where present is a natural or non-natural amino acid having an acidic side chain containing from 1 to 20 carbon atoms, or is a dicarboxylic acid containing up to 10 carbon atoms;

F may be absent, but where present is a natural or non-natural amino acid having an acidic side chain

containing from 1 to 20 carbon atoms, or is a dicarboxylic acid containing up to 10 carbon atoms; and

Z may be absent, -H, or a group of formula R_7CO-, where R_7 is a group containing from 1 to 20 carbon atoms which is chosen such that the group R_7CO- together with the nitrogen atom to which it is attached forms an amide, urethane or urea linkage;

(ii) 

where R_{13} is an aliphatic or aromatic group containing from 1 to 25, carbon atoms and 0-5 oxygen atoms, 0-3 nitrogen atoms, 0 to 2 sulphur atoms and up to 9 other heteroatoms which may be the same or different;

or a pharmaceutically acceptable salt or ester thereof.

2. An oligopeptide of Formula II or a salt or ester thereof according to claim 1 wherein R_1 is selected from:

3. An oligopeptide of Formula I or a salt or ester thereof according to claim 1 wherein X is selected from: $-CO_2H$, $-CONHCH_2Ph$, -H, -OH, $-NHSO_2R_{25}$ (where R_{25} is as defined in claim 1),



4. An oligopeptide of Formula I or a salt or ester thereof according to claim 3 wherein X is selected from: -H; -OH; -COOH, and $-NHSO_2R_{25}$.

5. An oligopeptide of Formula I or II or a salt or ester thereof according to any one of the preceding claims wherein B is selected from: glutamic acid and aspartic acid, 2-aminobutyric acid, 4,4-difluoro-2-aminobutyric acid, alanine, isoleucine, valine, leucine, cysteine, phenylalanine, naphthylalanine, β-cyclohexylalanine, and proline.

6. An oligopeptide, salt or ester according to claim 5 wherein B is selected from β-cyclohexylalanine, leucine, glutamic acid and 4,4-difluoro-2-aminobutyric acid.

7. An oligopeptide, salt or ester according to any one of the preceding claims, wherein Y is a group of formula:



and C is selected from: alanine, isoleucine, leucine, phenylalanine, valine, norleucine, norvaline, glutamic acid, glutamine, aspartic acid, α-t-butyl glycine, α-cinnamylglycine, homoleucine, 3,5 dichlorophenylalanine 2-thienylalanine, 3-bromophenylalanine and α-cyclopentyl glycine.

8. An oligopeptide, salt or ester according to claim 7 wherein C is selected from: isoleucine, glutamic acid, α-cyclopentylglycine, t-butyl glycine and valine.

9. An oligopeptide, salt or ester according to claim 7 or claim 8 wherein D is selected from: methionine, isoleucine, leucine, norleucine, valine, methyl valine,

phenylglycine or diphenylalanine.

10. An oligopeptide, salt or ester according to claim 9 wherein D is leucine or diphenylalanine.

11. An oligopeptide, salt or ester according to claim 9 or claim 10 wherein E is selected from glutamic acid, aspartic acid, succinic acid and glutaric acid.

12. An oligopeptide, salt or ester according to claim 11 wherein F is selected from glutamic acid, aspartic acid, succinic acid and glutaric acid.

13. A tripeptide of formula:

Z-C-B-A-X"

in which A, B, C and Z are as defined in claim 1 and X" is a carboxylic acid group ($-CO_2H$), amide group ($-CONR_9R_{10}$) or hydrogen; or a pharmaceutically acceptable salt or ester thereof.

14. A tripeptide, salt or ester according to claim 13 in which Z is a lower alkyloxy group or a group of formula:

$ArCH_2OCO-$ or $ArCH_2NHCO-$

wherein Ar is an optionally substituted aryl group.

15. A tripeptide, salt or ester according to claim 13 or 14 wherein the amino acid B is selected from: cyclohexylalanine, leucine, α-aminobutyric acid, 4,4-difluoro-2-aminobutyric acid and phenyl alanine.

16. A tripeptide, salt or ester according to any one of claims 13 to 15 wherein the amino acid C is selected from: alanine, isoleucine, leucine, phenylalanine, valine, norleucine, norvaline, glutamic acid, glutamine, aspartic acid, α-t-butyl glycine, styrylalanine,

homoleucine, 3,5 dichlorophenylalanine, 2-thienylalanine, 3-bromophenylalanine and α-cyclopentyl glycine.

17. A tripeptide according to any one of claims 13 to 16 wherein the combination of amino acids C-B is selected from:

isoleucine - cyclohexylalanine
isoleucine - leucine
isoleucine - α-aminobutyric acid
isoleucine - phenylalanine
leucine - leucine
phenylalanine - leucine
valine - leucine
norleucine - leucine
norvaline - leucine
glutamic acid - leucine
glutamine - leucine
n-butylaspartic acid - leucine
aspartic acid - leucine
t-butyl glycine - leucine
glutamic acid - 4,4 difluoro-2-aminobutyric acid
α-cinnamyl glycine - leucine
homoleucine - leucine
2-thienylalanine - leucine
3-bromophenylalanine - leucine
α-cyclopentylglycine - leucine.

18. A hexapeptide, salt or ester according to claim 1 having the formula:

Z-F-E-D-C-B-A-X or Z-F-E-D-C-B-A′-X′

where A-F, X and Z, A′ and X′ are as defined in claim 1.

19. A hexapeptide, salt or ester according to claim 18 wherein the group



is selected from:



and



20. A fluorine containing dipeptide according to Formula I of claim 1 wherein:

X is -COOH;

B is leucine; and

Y is a group of formula $R_{13}CO$- where R_{13} is as defined in claim 1;

or a pharmaceutically acceptable salt or ester thereof.

21. A dipeptide, salt, or ester according to claim 20

wherein R_{13} is a group of general formula



wherein each R_a is independently selected from hydrogen, lower alkyl, lower alkenyl, lower alkoxy, optionally substituted aryl or aralkyl groups or two R_a taken together result in the formation of a three to seven membered aliphatic or aromatic ring which optionally contains at least one heteroatom.

22. A dipeptide, salt or ester according to claim 21 wherein at least one group $-C(R_a)_2-$ is replaced by -O-.

23. A dipeptide, salt or ester according to claim 21 wherein R_{13} is a group of formula:



24. A dipeptide salt or ester according to claim 20 wherein R_{13} is a group of formula:

where R_{14} is a cycloalkyl or optionally substituted aryl group.

25. A dipeptide salt or ester according to claim 20 wherein R_{13} is a group selected from:

(a) 

where R_{15} is hydrogen, an optionally branched, optionally interrupted and optionally substituted lower alkyl or lower alkenyl group or an optionally substituted aralkyl group, R_{16} is hydrogen or an optionally substituted and optionally interrupted lower alkoxy or aryloxy- group;

(b) 

where R_{15} is as defined above; and

(c) 

where each of R_{17}, R_{18} and R_{19}, independently, is selected from hydrogen, optionally substituted lower alkyl, lower alkenyl and lower alkoxy, optionally substituted aryl, aralkyl, aryloxy or aralkoxy, a carboxylic acid group optionally as its lower alkyl ester, a halogen, cyano, or

CF_3 group.

26. A fluorine containing oligopeptide, salt or ester according to any one of the preceding claims for therapeutic use.

27. The use of a fluorine containing oligopeptide, salt or ester of any one of the preceding claims for the manufacture of a medicament for use in inhibiting the HCV NS3 protease, and/or for use in treating or preventing hepatitis C or a related condition.

28. A pharmaceutical composition comprising a fluorine containing oligopeptide, salt or ester according to any one of claims 1 to 25 and a pharmaceutically acceptable excipient, diluent or carrier.

29. A method of inhibiting HCV NS3 protease activity, and/or of treating or preventing hepatitis C or a related condition, the method comprising administering to a human or animal subject, a therapeutically or prophylactically effective amount of a composition according to claim 28, or of a fluorine containing oligopeptide salt or ester of any one of claims 1 to 25.

30. A method for the production of a compound of any one of claims 1 to 25 comprising reaction of a compound of formula Y-NH-CHR_2-CO_2H where R_2 is as defined in claim 1, optionally in a protected form, with an amine coreactant selected from:

(a) 

FORMULA K

where R' is a protecting group for a carboxylic acid group and R_1 is as defined in claim 1 and a ($-CH_2-$) group is optionally present at the position marked by brackets;

(b) 

FORMULA L

where R_1 is as defined in claim 1, and R^v is a group corresponding to, or convertible to X or X' of claim 1, and a ($-CH_2-$) group is optionally present at the position marked by brackets;

(c) 

FORMULA M

wherein R_1 is as defined in claim 1 and R" is a lower alkyl group and a ($-CH_2-$) group is optionally present at the position marked by brackets; and

(d) 

FORMULA N

wherein R_1 is as defined in claim 1 and a ($-CH_2-$) group is optionally present at the position marked by brackets.

SEQUENCE LISTING

<110> Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpA
Matassa, Victor
Narjes, Frank
Koehler, Konrad
Ontoria, Jesus
Poma, Marco

<120> Peptide inhibitors of hepatitis C virus NS3 protease

<130> KMN/FP5780044

<140>
<141>

<150> GB 9812523.0
<151> 1998-06-10

<160> 13

<170> PatentIn Ver. 2.1

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (3)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (4)
<223> Xaa is 4,4-difluoro-2-amino butyric acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 1
Xaa Glu Xaa Xaa
1

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (6)
<223> Xaa is 4,4-difluoro-2-amino butyric acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 2
Asp Glu Met Glu Glu Xaa
1 5

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (3)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (6)
<223> Xaa is 4,4-difluoro-2-amino butyric acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 3
Asp Glu Xaa Glu Xaa Xaa
1 5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (3)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (6)
<223> Xaa is a fluorinated hydrocarbon side chain

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 4
Asp Glu Xaa Glu Xaa Xaa
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (6)
<223> Xaa is a fluorinated hydrocarbon side chain

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 5
Asp Glu Met Glu Glu Xaa
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> Asp as tertiary butyl ester

<220>
<221> SITE
<222> (2, 4, 5)
<223> Glu as tertiary butyl ester

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 6
Asp Glu Met Glu Glu
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> Asp as tertiary butyl ester

<220>
<221> SITE
<222> (2, 4)
<223> Glu as tertiary butyl ester

<220>
<221> SITE
<222> (3)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is cyclohexylalanine

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 7
Asp Glu Xaa Glu Xaa
1 5

<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (17)
<223> AMIDATION

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 8
Lys Lys Lys Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu Ser Gly
1 5 10 15

Arg

<210> 9
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 9
Asp Glu Met Glu Glu Cys Ala Ser His Leu Pro Tyr Lys
1 5 10

<210> 10
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(3)
<223> Phenyalanines are linked by an ether bond

<220>
<221> SITE
<222> (4)
<223> Xaa is 4,4-difluoro-2-amino butyric acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 10
Phe Glu Phe Xaa
1

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (3)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (6)
<223> Xaa is 3-amino-5,5-difluoro-pentanoic acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 11
Asp Glu Xaa Glu Xaa Xaa
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (4)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is 4,4-difluoro-2-amino butyric acid

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 12
Glu Xaa Ile Xaa Xaa
1 5

<210> 13
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (3)
<223> Xaa is diphenylalanine

<220>
<221> SITE
<222> (5)
<223> Xaa is cyclohexylalanine

<220>
<221> SITE
<222> (6)
<223> Xaa is 4,4,4-trifluoro-2-amino- butyric acid

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 13

Asp Glu Xaa Glu Xaa Xaa

1 5

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 5/06, 5/08, 7/06, C07C 237/22, 311/45, C07D 209/26, 209/32, 307/94, 333/24, 407/12, 409/06, 409/12, A61K 38/05, 38/06, 38/08, 31/195, 31/335, 31/38, 31/405

A1

(11) International Publication Number: WO 99/64442

(43) International Publication Date: 16 December 1999 (16.12.99)

(21) International Application Number: PCT/GB99/01824

(22) International Filing Date: 9 June 1999 (09.06.99)

(30) Priority Data:
9812523.0 10 June 1998 (10.06.98) GB

(71) Applicant *(for all designated States except US)*: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. [IT/IT]; Via Pontina Km 30.600, I–00040 Pomezia (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MATASSA, Victor [GB/IT]; Via Panoramica, 44, I–00049 Velletri (IT). NARJES, Frank [DE/IT]; Via Pietro Nenni, 32, I–00040 Pomezia, (IT). KOEHLER, Konrad [US/SE]; Visättravägen 27, S–141 50 Huddinge (SE). ONTORIA, Jesus [ES/IT]; C/Deserto di Gobi, 65, I–00144 Roma (IT). POMA, Marco [IT/IT]; Via Collina del Valle, I–58019 Grosseto (IT). MARCHETTI, Antonella [IT/IT]; Via Pietro Nenni, 4c, I–00040 Pomezia (IT).

(74) Agents: NICHOLLS, Kathryn, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE

(57) Abstract

Fluorinated oligopeptides, especially those having 4,4–difluoro–2–amino butyric acid at the C terminus, may be effective inhibitors of hepatitis C virus NS3 protease. Examples of hexapeptides of the invention, optimised for binding in the S1 specificity pocket of the enzyme, may display IC_{50}s at the sub–micromolar level. Embodiments of tripeptides of the invention, having a keto–acid group at the C–terminus are, likewise, potent inhibitors of NS3 protease.

DECLARATION, POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE**, the specification of which [check one(s) applicable]

- X was filed 9 June 1999 as International Patent Application Serial No. PCT/GB99/01824, on which U.S. National Stage Application Serial No. 09/719,261 is based; and/or
- ___ was amended by Amendment filed _____ (if applicable); and/or
- ___ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) [37 C.F.R. §1.56(a)].

CLAIM UNDER 35 U.S.C. §119: I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed:

Prior Foreign Application(s) Appln No.	Country	Filing Date Day-Mon-Year	Priority Claimed Yes - No
9812523.0	Great Britain	10-06-1998	Yes

POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania, and the following individual(s) as my attorneys or agents with full power of substitution to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: **Patrick J. Hagan, Reg. No. 27,643 and Kathleen D. Rigaut, Ph.D., Reg. 43,047.**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO: **CUSTOMER NUMBER 000110**

DIRECT INQUIRIES TO: **Telephone: (215) 563-4100**
Facsimile: (215) 563-4044

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

Full Name Victor (First) G. (Middle) Matassa (Last)

Signature Victor G. Matassa

Date Feb 9th 2001

Residence Velletri, Rome, Italy (City, State or Country)

Citizenship U.K.

Post Office Address:
Via Panoramica 44 (Street Address)
Velletri Rome Italy 00049 (City, State or Country, Zip Code)

SECOND JOINT INVENTOR (IF ANY)

Full Name Frank (First) _____ (Middle) Narjes (Last)

Signature Frank Narjes

Date 27. Feb. 2001

Residence Ariccia Italy (City, State or Country)

Citizenship German

Post Office Address:
Viale dei Cervi 25 (Street Address)
Ariccia Rome, Italy 00040 (City, State or Country, Zip Code)

THIRD JOINT INVENTOR (IF ANY)

Full Name Konrad (First) Forster (Middle) ~~Koehler~~ (~~Last~~)

3 of 10

Signature Konrad H. Koehler

Date 5 February 2001

Residence ~~Huddinge~~ Sweden SE

City State or Country

Citizenship U.S.A.

Post Office Address:

Visätrravägen 27

Street Address

Huddinge Sweden SE-141 50

City State or Country Zip Code

FOURTH JOINT INVENTOR (IF ANY)

Full Name Jesus (First) Ontoria (Middle) (Last)

Signature

Date

Residence

City State or Country

Citizenship

Post Office Address:

Street Address

City State or Country Zip Code

FIFTH JOINT INVENTOR (IF ANY)

Full Name Marco (First) Poma (Middle) (Last)

Signature

Date

Residence

City State or Country

Citizenship

Post Office Address:

Street Address

City State or Country Zip Code

SIXTH JOINT INVENTOR (IF ANY)

Full Name Antonella (First) Marchetti (Middle) (Last)

Signature

Date

Residence

City State or Country

Citizenship

Post Office Address:

Street Address

City State or Country Zip Code

THIRD JOINT INVENTOR (IF ANY)

Full Name Konrad (First) _____ Koehler (Last)
(Middle)

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

FOURTH JOINT INVENTOR (IF ANY)

4th UNDISCLOSED

Full Name ~~Jesus~~ (First) _____ ~~Ontoria~~ (Last)
(Middle)

Signature Jesus M. Ontoria

Date 2nd February 2001

Residence BARCELONA SPAIN
City State or Country

Citizenship SPANISH

Post Office Address:

C/REMEI, 10-12, ESCALERA A, 1º-5ª
Street Address

BARCELONA SPAIN 08014
City State or Country Zip Code

FIFTH JOINT INVENTOR (IF ANY)

Full Name Marco (First) _____ Poma (Last)
(Middle)

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

SIXTH JOINT INVENTOR (IF ANY)

Full Name Antonella (First) _____ Marchetti (Last)
(Middle)

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

DECLARATION, POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE**, the specification of which [check one(s) applicable]

_X_ was filed 9 June 1999 as International Patent Application Serial No. PCT/GB99/01824, on which U.S. National Stage Application Serial No. 09/719,261 is based; and/or

___ was amended by Amendment filed _____ (if applicable); and/or

___ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) [37 C.F.R. §1.56(a)].

CLAIM UNDER 35 U.S.C. §119: I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed:

Prior Foreign Application(s)		**Filing Date**	**Priority Claimed**
Appln No.	**Country**	**Day-Mon-Year**	**Yes - No**
9812523.0	Great Britain	10-06-1998	Yes

POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania, and the following individual(s) as my attorneys or agents with full power of substitution to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: **Patrick J. Hagan, Reg. No. 27,643 and Kathleen D. Rigaut, Ph.D., Reg. 43,047.**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO: **CUSTOMER NUMBER 000110**

DIRECT INQUIRIES TO: **Telephone: (215) 563-4100**
Facsimile: (215) 563-4044

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

Full Name Victor (First) Matassa (Middle) (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) (State or Country) (Zip Code)

SECOND JOINT INVENTOR (IF ANY)

Full Name Frank (First) Narjes (Middle) (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) (State or Country) (Zip Code)

DECLARATION, POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE**, the specification of which [check one(s) applicable]

X was filed 9 June 1999 as International Patent Application Serial No. PCT/GB99/01824, on which U.S. National Stage Application Serial No. 09/719,261 is based; and/or

___ was amended by Amendment filed _____ (if applicable); and/or

___ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) [37 C.F.R. §1.56(a)].

CLAIM UNDER 35 U.S.C. §119: I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed:

Prior Foreign Application(s) Appln No.	Country	Filing Date Day-Mon-Year	Priority Claimed Yes - No
9812523.0	Great Britain	10-06-1998	Yes

POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania, and the following individual(s) as my attorneys or agents with full power of substitution to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: **Patrick J. Hagan, Reg. No. 27,643 and Kathleen D. Rigaut, Ph.D., Reg. 43,047.**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO: **CUSTOMER NUMBER 000110**

DIRECT INQUIRIES TO: **Telephone: (215) 563-4100**
Facsimile: (215) 563-4044

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

Full Name Victor (First) Matassa (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____

_____

SECOND JOINT INVENTOR (IF ANY)

Full Name Frank (First) Narjes (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) _____ (State or Country)

DECLARATION, POWER OF ATTORNEY AND POWER TO INSPECT

As a below named inventor, I hereby declare:

that my residence, post office address and citizenship are as stated below next to my name;

that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention entitled: **PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE**, the specification of which [check one(s) applicable]

_X_ was filed 9 June 1999 as International Patent Application Serial No. PCT/GB99/01824, on which U.S. National Stage Application Serial No. 09/719,261 is based; and/or

___ was amended by Amendment filed _____ (if applicable); and/or

___ is attached to this Declaration, Power of Attorney and Power to Inspect;

that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and

that I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Rule 56(a) [37 C.F.R. §1.56(a)].

CLAIM UNDER 35 U.S.C. §119: I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed:

Prior Foreign Application(s) Appln No.	Country	Filing Date Day-Mon-Year	Priority Claimed Yes - No
9812523.0	Great Britain	10-06-1998	Yes

POWER OF ATTORNEY: As inventor, I hereby appoint **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania, and the following individual(s) as my attorneys or agents with full power of substitution to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith: **Patrick J. Hagan, Reg. No. 27,643 and Kathleen D. Rigaut, Ph.D., Reg. 43,047.**

POWER TO INSPECT: I hereby give **DANN, DORFMAN, HERRELL AND SKILLMAN, P.C.** of Philadelphia, Pennsylvania or its duly accredited representatives power to inspect and obtain copies of the papers on file relating to this application.

SEND CORRESPONDENCE TO: **CUSTOMER NUMBER 000110**

DIRECT INQUIRIES TO: **Telephone: (215) 563-4100**
Facsimile: (215) 563-4044

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SOLE OR FIRST JOINT INVENTOR

Full Name Victor (First) Matassa (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) (State or Country) (Zip Code)

SECOND JOINT INVENTOR (IF ANY)

Full Name Frank (First) Narjes (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) (State or Country) (Zip Code)

THIRD JOINT INVENTOR (IF ANY)

Full Name Konrad (First) _____ Koehler (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) _____ (State or Country) _____ (Zip Code)

FOURTH JOINT INVENTOR (IF ANY)

Full Name Jesus (First) _____ Ontoria (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) _____ (State or Country) _____ (Zip Code)

5-(d)

FIFTH JOINT INVENTOR (IF ANY)

Full Name Marco (First) _____ Poma (Last)

Signature [signature]

Date 27 - Feb. 2001

Residence VIA COLLINA DEL VALLE (City) MONTE ARGENTARIO (GR) (State or Country) ITX

Citizenship ITALIANA

Post Office Address:

LUNGOTEVERE MELLINI 39 (Street Address)

ROMA (City) ITALY (State or Country) 00193 (Zip Code)

SIXTH JOINT INVENTOR (IF ANY)

Full Name Antonella (First) _____ Marchetti (Last)

Signature _____

Date _____

Residence _____ (City) _____ (State or Country)

Citizenship _____

Post Office Address:

_____ (Street Address)

_____ (City) _____ (State or Country) _____ (Zip Code)

THIRD [redacted] (IF ANY)

Full Name Konrad Koehler
First Middle Last

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

FOURTH JOINT INVENTOR (IF ANY)

Full Name Jesus Ontoria
First Middle Last

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

FIFTH JOINT INVENTOR (IF ANY)

Full Name Marco Poma
First Middle Last

Signature _____

Date _____

Residence _____
City State or Country

Citizenship _____

Post Office Address:

_____
Street Address

_____
City State or Country Zip Code

6 of

SIXTH JOINT INVENTOR (IF ANY)

Full Name Antonella Marchetti
First Middle Last

Signature Antonella Marchetti

Date 19-02-2001

Residence CASCIA (PG) ITALY I
City State or Country

Citizenship ITALIEN

Post Office Address:

V. TAGLIONI 15
Street Address

CASCIA (PG) ITALY 06043
City State or Country Zip Code